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ABSTRACT	  THE	  TUMOR-­‐SUPPRESSIVE	  PROPERTIES	  OF	  NEURAL	  STEM	  CELLS	  By	  Ryan	  Passino	  
	  Glioblastoma	  multiforme	  (GBM)	  is	  an	  aggressive	  central	  nervous	  system	  malignancy	  that	  commonly	  causes	  immune	  suppression	  in	  patients	  to	  avoid	  immune	  recognition	  and	  clearance.	  This	  complicates	  treatment	  options	  and	  limits	  the	  effectiveness	  of	  immunotherapy	  strategies.	  Interestingly,	  GBM	  formation	  can	  stimulate	  the	  neurogenic	  subventricular	  zone	  of	  the	  cerebral	  cortex	  and	  causes	  the	  proliferation	  and	  migration	  of	  neural	  stem	  cells	  (NSCs)	  towards	  the	  tumor.	  This	  migration	  reflects	  the	  NSC	  wound	  repair	  response	  following	  CNS	  injury.	  Studies	  using	  NSCs	  surgically	  implanted	  into	  GBM	  tumors	  showed	  decreased	  tumor	  growth	  and	  increased	  animal	  survival	  in	  mice;	  however,	  the	  mechanisms	  underlying	  these	  anti-­‐tumor	  properties	  of	  NSCs	  are	  unknown.	  Here	  we	  performed	  co-­‐culture	  proliferation	  assays	  in	  combination	  with	  gene	  expression	  analysis	  to	  show	  that	  there	  is	  a	  two-­‐way	  communication	  between	  the	  NSCs	  and	  glioma	  cells	  that	  results	  in	  decreased	  glioma	  proliferation	  and	  changes	  to	  survival	  and	  apoptotic-­‐related	  gene	  expression.	  These	  changes	  correlated	  with	  increased	  expression	  of	  tumor	  necrosis	  factor	  (TNF)	  superfamily	  death	  receptor	  ligands	  by	  the	  NSCs.	  NSCs	  also	  were	  found	  to	  express	  many	  immune-­‐related	  cytokines	  and	  chemokines	  involved	  in	  immune	  signaling,	  suggesting	  a	  potential	  role	  in	  mediating	  anti-­‐tumor	  immune	  responses.	  These	  results	  provide	  the	  first	  mechanistic	  evidence	  of	  NSC-­‐mediated	  tumor	  suppression.	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LITERATURE	  REVIEW	  AND	  BACKGROUND	  	  	  	  INTRODUCTION	  	  Glioblastoma	  multiforme	  (GBM)	  is	  classified	  as	  a	  grade	  IV	  astrocytoma,	  the	  most	  aggressive	  form	  of	  brain	  tumor	  in	  human	  with	  a	  poor	  prognosis	  due	  to	  the	  high	  probability	  of	  recurrence	  and	  few	  effective	  therapeutic	  treatments	  available.	  Standard	  treatment	  consisting	  of	  surgery,	  radiation,	  and	  chemotherapy	  results	  in	  a	  median	  survival	  of	  less	  than	  one	  year	  (Fine	  et	  al.,	  1993).	  The	  aggressiveness	  of	  GBMs	  is	  attributed	  to	  many	  mechanisms	  including	  increased	  metastasis,	  resistance	  to	  chemo	  and	  radiotherapy,	  and	  immune	  suppression.	  New	  treatment	  options	  are	  desperately	  needed	  to	  improve	  patient	  outcomes	  and	  recent	  attention	  to	  the	  role	  of	  endogenous	  neural	  stem	  cells	  as	  potential	  mediators	  of	  wound	  repair	  suggests	  that	  the	  CNS	  might	  have	  intrinsic	  abilities	  to	  suppress	  tumor	  growth.	  However,	  the	  mechanisms	  behind	  NSC-­‐mediated	  tumor	  suppression	  are	  unclear	  at	  this	  time	  and	  require	  further	  investigation.	  
	   NEURAL	  STEM	  CELLS	  Although	  it	  had	  previously	  been	  thought	  that	  the	  adult	  brain	  was	  incapable	  of	  generating	  new	  neurons,	  it	  is	  now	  accepted	  that	  neural	  stem	  cells	  (NSCs)	  continue	  to	  exist	  within	  the	  adult	  brain	  for	  cell	  replacement	  throughout	  life	  (Ming	  and	  Song,	  2005).	  Reynolds	  and	  Weiss	  were	  the	  first	  to	  demonstrate	  the	  neurogenic	  capability	  of	  the	  postnatal	  mouse	  brain	  by	  isolating	  NSCs	  from	  the	  striatum	  and	  expanding	  them	  in	  cultures	  containing	  epidermal	  growth	  factor	  (EGF)	  and	  fibroblast	  growth	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factor	  (FGF).	  These	  cells	  were	  proliferative,	  self-­‐renewing	  and	  expressed	  the	  intermediate	  filament	  marker	  nestin	  that	  is	  commonly	  expressed	  by	  neuroepithelial	  cells.	  These	  NSCs	  were	  also	  multipotent	  and	  able	  to	  generate	  new	  neurons	  and	  glial	  cells	  in	  vitro	  (Reynolds	  and	  Weiss,	  1992).	  Further	  research	  has	  recognized	  that	  NSC	  populations	  reside	  in	  two	  main	  neurogenic	  regions	  of	  the	  brain-­‐	  the	  subventricular	  zone	  (SVZ)	  of	  the	  lateral	  ventricles	  and	  the	  subgranular	  zone	  (SGZ)	  of	  the	  hippocampal	  dentate	  gyrus	  (Lois	  and	  Alvarez-­‐Buylla,	  1994)	  (Palmer	  et	  al.,	  1997).	  NSCs	  in	  the	  SVZ	  are	  located	  adjacent	  to	  the	  ependymal	  cells	  that	  line	  the	  lateral	  ventricles.	  These	  self-­‐renewing	  NSCs	  (type	  B)	  are	  the	  primary	  neural	  precursors	  that	  give	  rise	  to	  transit-­‐amplifying	  progenitor	  cells	  (type	  C),	  which	  further	  divide	  to	  generate	  immature	  neuroblasts	  (type	  A)	  (Doetsch	  et	  al.,	  1999).	  These	  neuroblasts	  migrate	  via	  the	  rostral	  migratory	  stream	  towards	  the	  olfactory	  bulb,	  where	  they	  continuously	  differentiate	  and	  replace	  granule	  and	  periglomerular	  interneurons	  that	  participate	  in	  these	  olfactory	  networks	  (Lois	  and	  Alvarez-­‐Buylla,	  1994).	  Adult	  neurons	  produced	  in	  the	  SGZ	  integrate	  directly	  into	  the	  granule	  layer	  of	  the	  dentate	  gyrus	  and	  facilitate	  long-­‐term	  potentiation	  and	  the	  stimulation	  of	  learning	  and	  memory	  (Imayoshi	  et	  al.,	  2008).	  NSCs	  also	  participate	  in	  wound	  repair	  following	  brain	  insults	  such	  as	  trauma	  or	  disease.	  Following	  injury,	  the	  neurogenic	  regions	  are	  stimulated,	  resulting	  in	  NSC	  proliferation	  and	  redirected	  migration	  towards	  the	  damaged	  areas	  where	  they	  promote	  neurogenesis	  (Kernie	  and	  Parent,	  2010)	  (Dash	  et	  al.,	  2001).	  Similar	  patterns	  of	  wound	  repair	  occur	  in	  models	  of	  traumatic	  brain	  injury	  and	  stroke,	  as	  well	  as	  neurological	  conditions	  such	  as	  multiple	  sclerosis.	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Multiple	  studies	  are	  now	  examining	  the	  role	  of	  NSCs	  during	  wound	  repair	  within	  the	  CNS	  and	  their	  potential	  use	  in	  cell	  replacement	  therapies.	  	   NEURAL	  STEM	  CELL	  MIGRATION	  Interestingly,	  glioblastoma	  models	  in	  mice	  suggest	  that	  GBM	  tumors	  also	  stimulate	  NSC	  activity	  within	  the	  SVZ	  and	  show	  that	  NSCs	  are	  diverted	  from	  their	  normal	  migratory	  path	  and	  exhibit	  strong	  tropism	  for	  the	  tumor.	  Aboody	  et	  al.	  first	  reported	  on	  the	  strong	  tropic	  capacity	  of	  NSCs	  for	  intracranial	  tumors	  by	  demonstrating	  that	  NSCs	  implanted	  at	  distant	  locations	  in	  the	  mouse	  brain	  could	  preferentially	  target	  the	  tumor	  mass	  located	  in	  the	  frontal	  lobe.	  LacZ-­‐expressing	  NSCs	  implanted	  into	  either	  the	  contralateral	  hemisphere	  or	  the	  cerebral	  ventricles	  were	  observed	  migrating	  through	  normal	  tissue	  and	  dispersing	  throughout	  the	  tumor.	  NSCs	  also	  ‘tracked	  down’	  individual	  glioma	  cells	  that	  had	  infiltrated	  beyond	  the	  edges	  of	  the	  tumor	  mass	  and	  into	  normal	  tissue.	  Surprisingly,	  NSCs	  could	  even	  target	  the	  tumor	  from	  within	  systemic	  circulation.	  When	  injected	  into	  circulation	  through	  the	  tail	  vein,	  the	  labeled	  NSCs	  were	  found	  distributed	  throughout	  the	  intracerebral	  tumor	  mass	  after	  four	  days	  (Aboody	  et	  al.,	  2000).	  	  	  Work	  by	  Glass	  et	  al.	  further	  supports	  the	  idea	  that	  NSCs	  have	  tumor	  tropic	  capabilities	  and	  also	  potential	  tumor-­‐suppressive	  properties.	  Using	  transgenic	  mice	  expressing	  green	  fluorescent	  protein	  labeled	  nestin	  (GFP-­‐nestin)	  along	  with	  DsRed-­‐labeled	  GL261	  GBM	  cells	  to	  distinguish	  between	  nestin-­‐positive	  NSCs	  and	  the	  cancer	  cells,	  they	  first	  demonstrated	  that	  endogenous	  NSCs	  could	  migrate	  from	  the	  SVZ	  to	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the	  tumors.	  Nestin	  is	  a	  specific	  cell	  marker	  used	  for	  labeling	  NSCs	  and	  is	  primarily	  expressed	  within	  the	  neurogenic	  regions	  of	  the	  brain.	  Furthermore,	  the	  fluorescent	  dye	  DiI	  was	  also	  administered	  into	  the	  ventricle	  to	  ensure	  that	  nestin-­‐positive	  cells	  arriving	  at	  the	  tumor	  only	  originated	  from	  the	  SVZ.	  Two	  weeks	  post-­‐operation,	  the	  tumor	  was	  completely	  surrounded	  by	  a	  dense	  layer	  of	  DiI/Nestin-­‐positive	  cells,	  and	  many	  close	  interactions	  between	  the	  NSCs	  and	  the	  glioma	  cells	  were	  observed	  (Glass	  et	  al.,	  2005).	  In	  support	  of	  this	  data,	  Ehtesham	  et	  al.	  showed	  that	  NSC	  tropism	  for	  glioblastomas	  is	  mediated	  by	  CXCR4/SDF-­‐1	  and	  many	  additional	  factors	  produced	  by	  the	  GBM,	  including	  FGF	  and	  vascular	  endothelial	  growth	  factor	  (VEGF)	  (Ehtesham	  et	  al.,	  2004).	  Along	  with	  chemotactic	  proteins	  and	  growth	  factors,	  cancerous	  cells	  themselves	  appear	  to	  induce	  NSC	  migration.	  When	  glioma	  cells	  were	  fractionated	  to	  test	  their	  chemotactic	  properties,	  the	  cellular	  membrane	  induced	  stem	  cell	  migration	  at	  levels	  comparable	  to	  FGF	  and	  serum	  (Spaeth	  et	  al.,	  2008).	  Taken	  together,	  this	  work	  strongly	  supports	  the	  idea	  that	  the	  endogenous	  NSCs	  possess	  the	  ability	  to	  respond	  and	  move	  toward	  GBM	  tumors	  in	  vivo.	  	  NSC	  migration	  towards	  the	  tumor	  appears	  to	  reflect	  a	  wound	  repair	  response	  that	  may	  be	  influenced	  by	  the	  conditions	  that	  arise	  from	  tumor	  formation,	  including	  inflammation,	  hypoxia,	  and	  tissue	  necrosis.	  The	  tumor	  microenvironment	  experiences	  reduced	  oxygen	  concentrations	  (hypoxia)	  as	  a	  result	  of	  the	  rapid	  proliferation	  rate	  of	  cancer	  cells	  leading	  to	  insufficient	  blood	  and	  oxygen	  supply.	  This	  hypoxia	  regulates	  the	  expression	  of	  hypoxia-­‐inducible	  factors	  (HIF)-­‐	  dimeric	  transcription	  factors	  comprised	  of	  the	  hypoxic	  response	  factor	  HIF-­‐1α	  and	  the	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constitutively	  expressed	  aryl	  hydrocarbon	  receptor	  nuclear	  translocator	  (ARNT).	  HIF-­‐1	  is	  regulated	  by	  a	  prolyl	  hydroxylase	  domain	  (PHD),	  which	  under	  normoxic	  conditions	  uses	  oxygen	  to	  selectively	  hydroxylate	  the	  proline	  residues	  of	  HIF-­‐1.	  This	  form	  of	  HIF-­‐1	  can	  interact	  with	  Von	  Hippel-­‐Lindau	  (VHL)	  protein,	  which	  causes	  HIF-­‐1	  to	  become	  ubiquitylated	  and	  targeted	  for	  proteosomal	  degradation.	  Under	  hypoxic	  conditions,	  HIF	  is	  stabilized	  and	  can	  up-­‐regulate	  the	  transcription	  of	  target	  genes	  including	  VEGF	  for	  angiogenesis,	  lactate	  dehydrogenase-­‐A	  (LDH-­‐A)	  for	  increasing	  glycolysis,	  and	  glucose	  transporter-­‐1,3	  (GLUT1,	  GLUT3)	  for	  increased	  glucose	  uptake	  (Harris,	  2002).	  	  NSC	  maintenance	  and	  migration	  are	  also	  influenced	  by	  hypoxia-­‐inducible	  factors.	  The	  hypoxic	  stem	  cell	  niche	  enhances	  survival	  and	  proliferation	  of	  NSCs	  along	  with	  maintaining	  multipotency	  through	  HIF-­‐2α	  regulation	  of	  Oct4	  (Covello	  et	  al.,	  2006;	  Pistollato	  et	  al.,	  2007)	  (Mohyeldin	  et	  al.,	  2010).	  CXCR4	  expression	  is	  increased	  after	  exposing	  NSCs	  to	  hypoxia	  (Zhao	  et	  al.,	  2008)	  and	  CXCR4	  up-­‐regulation	  correlates	  with	  enhanced	  migration	  to	  glioma-­‐conditioned	  media	  and	  also	  to	  ischemic	  areas	  in	  
vivo,	  where	  stromal	  cell-­‐derived	  factor	  (SDF-­‐1)	  is	  increased	  by	  HIF-­‐1	  overexpression	  (Ceradini	  et	  al.,	  2004).	  Knocking	  down	  HIF-­‐1	  with	  interfering	  RNA	  blocked	  the	  hypoxia-­‐induced	  migration	  of	  NSCs	  (Zhao	  et	  al.,	  2008).	  	  Along	  with	  inducing	  the	  migration	  of	  NSCs	  through	  hypoxia-­‐inducible	  factors	  and	  chemotactic	  receptors,	  the	  hypoxic	  tumor	  microenvironment	  also	  causes	  cellular	  necrosis	  and	  the	  release	  of	  damage-­‐associated	  molecular	  patterns	  (DAMPs)	  that	  act	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as	  danger	  signals	  and	  have	  chemotactic	  properties	  on	  stem	  cells	  and	  immune	  cells	  to	  promote	  an	  immune	  response.	  One	  of	  the	  more	  important	  DAMPs	  released	  from	  necrotic	  tissue	  is	  the	  high-­‐mobility	  group	  box-­‐1	  protein	  (HMGB1).	  HMGB1	  is	  a	  non-­‐histone	  DNA-­‐binding	  protein	  normally	  located	  within	  the	  nucleus.	  HMGB1	  can	  be	  released	  from	  cells	  stimulated	  with	  bacterial	  endotoxin	  and	  is	  a	  ligand	  for	  the	  receptor	  for	  advanced	  glycation	  end	  products	  (RAGE)	  (Taguchi	  et	  al.,	  2000)	  (Wang	  et	  al.,	  1999).	  Release	  of	  HMGB1	  from	  necrotic	  cells	  stimulates	  the	  proliferation	  and	  migration	  of	  stem	  cells	  (Pistoia	  and	  Raffaghello,	  2011)	  (Lotfi	  et	  al.,	  2011;	  Meng	  et	  al.,	  2008).	  These	  functions	  are	  lost	  upon	  HMGB1	  oxidation,	  although	  it	  is	  thought	  that	  the	  hypoxic	  conditions	  of	  the	  tumor	  microenvironment	  preserve	  its	  functionality	  (Lotfi	  et	  al.,	  2011).	  Along	  with	  signaling	  injury,	  HMGB1	  also	  serves	  as	  a	  tumor	  antigen	  that	  mediates	  antitumor	  immune	  responses,	  as	  discussed	  later.	  
	   TUMOR	  SUPPRESSION	  The	  discovery	  that	  NSCs	  migrate	  strongly	  towards	  intracranial	  tumors	  suggests	  a	  new	  strategy	  for	  delivering	  anti-­‐tumor	  drugs	  with	  genetically	  modified	  NSCs.	  Benedetti	  et	  al.	  isolated	  neural	  precursors	  from	  C57BL6J	  mice	  and	  overexpressed	  immune-­‐related	  interleukin-­‐4	  (IL-­‐4)	  cDNA	  or	  lysosomal	  enzyme	  galactocerebrosidase	  (GALC)	  as	  a	  control.	  IL-­‐4	  was	  used	  for	  its	  reportedly	  strong	  antitumor	  and	  dendritic	  cell	  induction	  effect	  (Benedetti	  et	  al.,	  1999)	  (Sallusto	  and	  Lanzavecchia,	  1994).	  Mice	  receiving	  IL4-­‐NSCs	  along	  with	  GL261	  glioma	  cell	  injection	  showed	  a	  significant	  increase	  in	  survival	  compared	  to	  control	  mice	  not	  receiving	  NSCs.	  Interestingly,	  mice	  receiving	  unmodified	  control	  NSCs	  co-­‐injected	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with	  GL261	  cells	  also	  experienced	  a	  significant	  increase	  in	  survival	  and	  a	  reduction	  in	  tumor	  size	  relative	  to	  controls.	  It	  was	  then	  concluded	  that	  NSCs	  could	  possess	  intrinsic	  antitumor	  properties	  and	  might	  release	  factors	  that	  can	  suppress	  tumor	  cell	  growth	  (Benedetti	  et	  al.,	  2000)	  (Noble,	  2000).	  NSCs	  respond	  to	  the	  tumor	  microenvironment	  by	  proliferating	  and	  expressing	  high	  levels	  of	  the	  nuclear	  protein	  Ki-­‐67,	  which	  is	  associated	  with	  cell	  cycle	  progression	  and	  proliferation	  of	  NSCs	  (Glass	  et	  al.,	  2005).	  This	  response	  does	  not	  require	  direct	  contact	  between	  cells	  as	  it	  was	  shown	  by	  Venugopal	  et	  al.	  that	  NSCs	  treated	  with	  GBM-­‐conditioned	  media	  in	  
vitro	  were	  transiently	  transformed,	  resulting	  in	  larger	  neurosphere	  formation,	  increased	  cell	  proliferation	  and	  increased	  self-­‐renewal	  capacity	  (Venugopal	  et	  al.,	  2012).	  	  An	  important	  study	  by	  Glass	  et	  al.	  demonstrated	  that	  the	  association	  of	  NSCs	  with	  glioblastomas	  results	  in	  reduced	  tumor	  size	  and	  increased	  survival	  in	  mouse	  models.	  These	  antitumor	  effects	  were	  first	  studied	  in	  vitro	  using	  co-­‐culture	  assays	  and	  they	  found	  that	  NSCs	  decreased	  GBM	  proliferation	  rates	  and	  strongly	  induced	  GBM	  apoptosis	  (Glass	  et	  al.,	  2005).	  They	  also	  found	  a	  correlation	  between	  mouse	  age	  and	  tumor	  aggression.	  It	  was	  observed	  that	  younger	  mice	  had	  significantly	  higher	  survival	  rates	  than	  older	  mice.	  These	  results	  corresponded	  with	  data	  showing	  decreasing	  levels	  of	  nestin-­‐positive	  cells	  surrounding	  the	  tumor	  as	  the	  age	  of	  the	  mice	  increased.	  The	  older	  P180	  mice	  had	  significantly	  fewer	  tumor-­‐associated	  NSCs	  (20%)	  and	  tumor	  volumes	  2.5	  times	  larger	  than	  the	  younger	  P25	  mice.	  In	  another	  study,	  Staflin	  et	  al.	  showed	  that	  embryonic	  hippocampal	  NSCs	  prolonged	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animal	  survival	  and	  completely	  inhibited	  the	  outgrowth	  of	  glioma	  cells	  in	  25%	  of	  cases.	  The	  delayed	  tumor	  outgrowth	  was	  observed	  when	  the	  NSCs	  were	  inoculated	  into	  a	  developed	  tumor	  and	  also	  when	  first	  mixed	  and	  then	  co-­‐injected	  (Staflin	  et	  al.,	  2004).	  	  It	  is	  known	  that	  the	  activity	  of	  neurogenesis	  in	  the	  adult	  brain	  declines	  with	  increasing	  age	  (Hallbergson	  et	  al.,	  2003)	  (Maslov	  et	  al.,	  2004)	  and	  that	  age	  is	  an	  important	  prognostic	  factor	  in	  predicting	  the	  survival	  from	  glioblastoma	  (Kleihues	  et	  al.,	  1993).	  To	  determine	  whether	  the	  correlation	  between	  increasing	  age	  and	  tumor	  aggressiveness	  is	  due	  to	  a	  weakened	  NSC	  response,	  Glass	  et	  al.	  supplemented	  the	  tumor	  cell	  inoculant	  with	  NSCs	  (1:3)	  for	  the	  P180	  age	  group.	  The	  survival	  time	  of	  these	  new	  subjects	  was	  significantly	  increased	  compared	  to	  the	  control	  group	  and	  similar	  to	  the	  younger	  mice	  (Glass	  et	  al.,	  2005).	  Taken	  together,	  this	  data	  suggests	  that	  NSCs	  have	  tumor-­‐suppressive	  properties	  but	  the	  effect	  is	  attenuated	  as	  the	  NSC	  population	  declines	  with	  age.	  	   MECHANISMS	  OF	  SUPPRESSION	  While	  multiple	  studies	  have	  reported	  on	  the	  tumor-­‐suppressive	  properties	  of	  NSCs,	  the	  mechanisms	  behind	  this	  suppression	  are	  currently	  unknown.	  We	  propose	  that	  NSC	  migration	  and	  tumor	  suppression	  represents	  a	  wound	  repair	  response	  that	  is	  influenced	  by	  the	  conditions	  of	  the	  tumor	  microenvironment	  such	  as	  inflammation,	  hypoxia,	  and	  tissue	  necrosis.	  Coincidently,	  cancer	  has	  been	  described	  by	  early	  pathologists	  as	  an	  aberrant	  wound	  that	  never	  completely	  heals	  (Dvorak,	  1986).	  This	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analogy	  suggests	  that	  a	  proper	  repair	  response	  towards	  the	  tumor	  could	  effectively	  eliminate	  it.	  Therefore,	  the	  wound	  repair	  process	  will	  be	  reviewed	  in	  attempt	  to	  apply	  this	  model	  towards	  NSC-­‐mediated	  tumor	  suppression.	  	  Aside	  from	  cell	  replacement,	  NSCs	  are	  reportedly	  involved	  in	  modulating	  the	  immune	  response	  during	  CNS	  wound	  repair	  (Martino	  et	  al.,	  2011).	  Following	  brain	  or	  spinal	  cord	  injury,	  local	  astrocytes	  and	  microglia	  respond	  to	  molecules	  released	  from	  damaged	  or	  necrotic	  cells	  and	  initiate	  the	  innate	  immune	  responses	  by	  producing	  cytokines	  and	  chemokines	  that	  promote	  inflammation	  and	  recruit	  peripheral	  immune	  cells	  to	  the	  injury	  site	  (Aarum	  et	  al.,	  2003)	  (Olson	  and	  Miller,	  2004).	  Damaged	  tissues	  also	  stimulate	  the	  neurogenic	  regions	  of	  the	  brain,	  prompting	  the	  proliferation	  and	  migration	  of	  NSCs	  towards	  the	  damaged	  tissue.	  The	  activation	  of	  NSCs	  could	  also	  result	  from	  cross	  talk	  with	  microglia	  and	  the	  signaling	  molecules	  they	  produce.	  Aaurum	  et	  al.	  found	  that	  soluble	  factors	  present	  within	  microgilal-­‐conditioned	  media	  induce	  NSC	  migration	  and	  Belmadani	  et	  al.	  later	  reported	  that	  tumor	  necrosis	  factor-­‐α	  (TNFα)	  and	  interferon-­‐γ	  (IFN-­‐γ)	  produced	  by	  activated	  astrocytes	  and	  microglia	  caused	  this	  migratory	  response	  (Aarum	  et	  al.,	  2003)	  (Belmadani	  et	  al.,	  2006).	  NSCs	  within	  the	  SVZ	  express	  the	  chemotactic	  receptors	  and	  adhesion	  molecules	  needed	  for	  immune	  signaling,	  including	  CXCR4,	  CCR2,	  CCR5,	  and	  CX3CR1	  (Ji	  et	  al.,	  2004).	  This	  suggests	  that	  NSCs	  possess	  the	  necessary	  cellular	  machinery	  to	  respond	  to	  the	  signals	  released	  from	  the	  damaged	  tissues	  and	  the	  ability	  to	  move	  towards	  the	  injury	  site.	  Not	  surprisingly,	  many	  of	  the	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same	  molecules	  used	  in	  recruiting	  innate	  immune	  cells	  to	  damaged	  tissue	  are	  also	  found	  within	  the	  tumor	  microenvironment	  (Spaeth	  et	  al.,	  2008).	  	  	  At	  the	  site	  of	  injury,	  damage-­‐associated	  molecular	  patterns	  (DAMPs)-­‐	  endogenous	  molecules	  released	  from	  damaged	  cells-­‐	  act	  as	  danger	  signals	  and	  are	  recognized	  by	  macrophages/microglia	  and	  immune	  cells	  via	  toll-­‐like	  receptors	  (TLRs).	  TLRs	  are	  integral	  membrane	  glycoproteins	  containing	  an	  extracellular	  domain	  with	  leucine-­‐rich-­‐repeats	  motifs	  and	  a	  cytoplasmic	  Toll/IL-­‐1R	  (TIR)	  signaling	  domain,	  named	  for	  its	  homology	  to	  the	  interleukin	  1	  receptor	  (IL-­‐1R).	  The	  expression	  of	  these	  receptors	  is	  dynamic	  and	  can	  be	  rapidly	  increased	  in	  response	  to	  pathogens,	  cytokines,	  and	  environmental	  stressors.	  The	  effector	  response	  following	  TLR	  activation	  is	  normally	  related	  to	  immune	  function	  (Akira	  et	  al.,	  2006).	  There	  are	  multiple	  TLR	  subtypes	  that	  bind	  different	  damage	  and	  pathogen-­‐associated	  molecular	  patterns	  and	  produce	  different	  effector	  responses.	  For	  example,	  TLR1,	  TLR2,	  and	  TLR6	  recognize	  lipids,	  whereas	  TLR7,	  TLR8,	  and	  TLR9	  recognize	  nucleic	  acids.	  TLR4	  is	  more	  divergent	  and	  can	  recognize	  lipopolysaccharides	  (LPS),	  fibronectin,	  and	  heat-­‐shock	  proteins	  (Akira	  et	  al.,	  2006).	  Damage-­‐associated	  HMGB1	  protein,	  commonly	  released	  from	  damaged	  tissue	  and	  necrotic	  tumor	  cells,	  can	  bind	  and	  activate	  both	  TLR2	  and	  TLR4	  (Apetoh	  et	  al.,	  2007;	  Curtin	  et	  al.,	  2009).	  TLRs	  are	  highly	  expressed	  by	  macrophages	  and	  dendritic	  cells	  and	  also	  throughout	  the	  CNS	  by	  microglia,	  astrocytes,	  and	  oligodendrocytes	  (Bsibsi	  et	  al.,	  2002).	  Importantly,	  NSCs	  also	  express	  TLR2	  and	  TLR4	  and	  they	  are	  reported	  to	  be	  important	  for	  neurogenesis	  (Akira	  et	  al.,	  2006)	  (Rolls	  et	  al.,	  2007).	  TLR2	  is	  primarily	  involved	  in	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cell-­‐fate	  decisions	  while	  TLR4	  affects	  both	  cellular	  proliferation	  and	  differentiation	  (Rolls	  et	  al.,	  2007).	  Activation	  of	  TLRs	  leads	  to	  the	  recruitment	  of	  the	  intracellular	  adaptor	  protein	  myeloid	  differentiation	  factor	  88	  (MyD88)	  and	  its	  association	  with	  protein	  kinases	  IRAK	  and	  TRAF6.	  The	  IRAK1-­‐TRAF6	  complex	  activates	  the	  downstream	  protein	  kinase	  TAK1	  complex,	  resulting	  in	  the	  phosphorylation	  of	  IKK	  and	  the	  subsequent	  activation	  of	  nuclear	  factor-­‐kappa-­‐B	  (NF-­‐ĸB)	  (Akira	  et	  al.,	  2006).	  	  NF-­‐ĸB	  is	  a	  family	  of	  master	  transcription	  factors	  that	  regulate	  the	  expression	  of	  many	  immune-­‐related	  genes	  involved	  with	  inflammatory	  responses,	  cytokines/chemokines,	  stress	  response,	  survival,	  apoptosis,	  proliferation	  and	  differentiation.	  The	  dimeric	  transcription	  factors	  include	  NF-­‐κB1/p50,	  NF-­‐κB2/p52,	  RelA/p65,	  and	  RelB.	  The	  Rel	  factors	  mediate	  dimerization,	  nuclear	  localization,	  DNA	  binding	  and	  interactions	  with	  the	  I-­‐kB	  inhibitory	  proteins.	  These	  inhibitors	  bind	  to	  Rel	  homology	  domains	  (RHD)	  on	  the	  Rel	  components	  to	  mask	  the	  nuclear	  location	  sequences,	  thereby	  restricting	  the	  NF-­‐κB	  dimers	  inactive	  in	  the	  cytoplasm.	  Activating	  signals	  including	  exogenous	  and	  endogenous	  ligands	  along	  with	  physical	  and	  chemical	  stresses	  can	  direct	  the	  degradation	  of	  I-­‐kB	  through	  the	  activation	  of	  IKK	  (IkB	  kinase).	  These	  regulatory	  kinases	  are	  comprised	  of	  a	  heteromer	  of	  two	  related	  IkB	  kinase	  domains	  and	  a	  regulatory	  NEMO	  domain	  (Hayden	  and	  Ghosh,	  2008;	  Wajant	  et	  al.,	  2003).	  	  Activated	  macrophages/microglia	  and	  dendritic	  cells	  respond	  to	  TLR	  and	  downstream	  NF-­‐κB	  activation	  by	  initiating	  the	  pro-­‐inflammatory	  response	  through	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cytokine	  production	  and	  immune	  cell	  recruitment.	  Key	  pro-­‐inflammatory	  cytokines	  involved	  include	  tumor	  necrosis	  factor-­‐α	  (TNFα),	  interferon-­‐γ	  (INF-­‐γ),	  interleukin-­‐6	  (IL-­‐6),	  and	  IL-­‐1β	  (Carpentier	  and	  Palmer,	  2009)	  and	  important	  chemokines	  for	  immune	  cell	  recruitment	  include	  RANTES	  (CCL5),	  MIP-­‐2	  (CXCL2),	  MIP-­‐1a	  (CCL3),	  monocyte	  chemo-­‐attractant	  protein	  1	  (MCP-­‐1)	  (CCL2),	  and	  interleukin-­‐8	  (CXCL8)	  (Spaeth	  et	  al.,	  2008).	  This	  early	  pro-­‐inflammatory	  response	  is	  important	  for	  recruiting	  innate	  and	  adaptive	  immune	  cells,	  activating	  reactive	  gliosis,	  clearing	  cellular	  debris,	  up-­‐regulating	  co-­‐stimulatory	  signals	  and	  MHC	  II	  protein	  expression,	  and	  activating	  the	  adaptive	  immune	  responses	  to	  eliminate	  potential	  pathogens	  (Aarum	  et	  al.,	  2003)	  (Akira	  et	  al.,	  2006)	  (Babcock	  et	  al.,	  2003)	  (Bsibsi	  et	  al.,	  2002)	  (Olson	  and	  Miller,	  2004).	  	  The	  effects	  of	  pro-­‐inflammatory	  cytokines	  have	  been	  tested	  on	  NSCs	  to	  determine	  how	  they	  respond	  to	  the	  conditions	  of	  the	  wound	  during	  the	  repair	  process.	  Widera	  et	  al.	  demonstrated	  that	  TNFα	  has	  a	  positive	  influence	  on	  NSC	  proliferation,	  indicated	  by	  neurosphere	  volume	  and	  the	  incorporation	  of	  bromodeoxyuridin	  (BrdU)	  into	  the	  proliferating	  NSCs.	  They	  also	  found	  that	  TNFα	  up-­‐regulates	  cyclin	  D1	  expression	  through	  the	  NF-­‐κB	  signaling	  pathway	  and	  that	  inhibition	  of	  NF-­‐κB	  with	  IkB-­‐AA1	  strongly	  attenuated	  this	  effect	  (Widera	  et	  al.,	  2006).	  Another	  important	  study	  by	  Covacu	  et	  al.	  tested	  the	  responsiveness	  of	  NSC	  to	  cytokines	  by	  measuring	  the	  expression	  levels	  of	  TLR	  proteins	  following	  treatment	  with	  macrophage	  supernatants,	  pro-­‐inflammatory	  cytokines	  IFN-­‐γ	  and/or	  TNFα,	  and	  agonists	  for	  TLR2	  and	  TLR4.	  	  TLR2	  expression	  was	  increased	  by	  activated	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macrophage	  supernatant	  and	  by	  TNFα	  alone	  and	  synergistically	  with	  IFN-­‐γ.	  TLR4	  expression	  was	  increased	  by	  IFN-­‐γ	  but	  was	  decreased	  by	  TNFα	  (Covacu	  et	  al.,	  2009).	  Neural	  stem	  cells	  not	  only	  respond	  positively	  to	  inflammatory	  cytokines,	  but	  they	  can	  also	  contribute	  to	  the	  immune	  signaling	  by	  producing	  TNFα	  when	  stimulated	  with	  TLR	  agonists.	  NSCs	  have	  also	  been	  found	  to	  produce	  additional	  pro-­‐inflammatory	  (IL-­‐1α,	  IL-­‐1β,	  IL-­‐6)	  along	  with	  anti-­‐inflammatory	  cytokines	  (TGF-­‐β1,	  and	  β2)	  when	  examined	  in	  vitro	  using	  RT-­‐PCR	  and	  ELISA	  assays	  (Klassen	  et	  al.,	  2003).	  Taken	  together,	  these	  data	  suggests	  an	  important	  role	  for	  NSCs	  in	  promoting	  and	  regulating	  immune	  responses	  during	  wound	  repair.	  	  Multiple	  in	  vivo	  studies	  have	  investigated	  the	  therapeutic	  potential	  of	  NSCs	  for	  the	  treatment	  of	  neurological	  disorders	  such	  as	  ischemic	  stroke,	  spinal	  cord	  injury,	  and	  multiple	  sclerosis.	  Most	  studies	  suggest	  that	  the	  effects	  of	  NSCs	  appear	  to	  be	  context-­‐dependent	  and	  are	  mediated	  through	  a	  bystander	  effect,	  where	  the	  NSCs	  provide	  neuroprotection	  through	  trophic	  support	  and	  immune	  regulation	  rather	  than	  providing	  cellular	  replacement	  or	  engraftment.	  Transplanted	  NSCs	  were	  found	  to	  support	  host	  axonal	  regeneration	  after	  spinal	  cord	  injury	  by	  producing	  neurotrophic	  factors	  such	  as	  nerve	  growth	  factor	  (NGF),	  brain-­‐derived	  neurotrophic	  factor	  (BDNF),	  ciliary	  neurotrophic	  factor	  (CNTF),	  and	  glial	  cell-­‐derived	  neurotrophic	  factor	  (GDNF)	  (Lu	  et	  al.,	  2003).	  In	  addition	  to	  the	  production	  of	  soluble	  paracrine	  factors,	  secreted	  microvesicles	  serve	  as	  important	  mediators	  in	  cellular	  communication.	  Composed	  of	  small	  membrane	  vesicles	  derived	  from	  larger	  multivesicular	  bodies,	  these	  microvesicles	  can	  transport	  proteins	  and	  genetic	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materials	  such	  as	  messenger	  and	  micro-­‐RNAs	  to	  surrounding	  cells	  and	  tissues.	  Because	  microvesicles	  are	  produced	  by	  stem	  cells,	  they	  represent	  a	  novel	  mechanism	  by	  which	  NSCs	  may	  promote	  wound	  repair	  within	  the	  CNS	  (Drago	  et	  al.,	  2013)	  (Sabin	  and	  Kikyo,	  2014).	  	  	  Along	  with	  immune	  signaling	  and	  trophic	  support,	  there	  is	  evidence	  that	  NSCs	  could	  promote	  regeneration	  through	  their	  ability	  to	  regulate	  immune	  cell	  function.	  Injuries	  to	  the	  CNS	  are	  often	  found	  to	  have	  unregulated	  chronic	  inflammation	  that	  prevents	  complete	  regeneration.	  It	  was	  reported	  that	  NSC	  transplantation	  can	  improve	  locomotor	  function	  following	  spinal	  cord	  injury	  and	  that	  this	  recovery	  was	  attributed	  to	  NSC-­‐immune	  cell	  communication	  and	  regulation	  (Cusimano	  et	  al.,	  2012).	  Moreover,	  it	  was	  found	  that	  NSC	  transplantation	  during	  the	  acute	  phase	  of	  early	  inflammation	  following	  injury	  led	  to	  significant	  recovery	  by	  regulating	  levels	  of	  inflammatory	  messenger	  RNA	  in	  activated	  macrophages	  (Cusimano	  et	  al.,	  2012).	  The	  effect	  of	  NSCs	  in	  the	  tumor	  microenvironment	  with	  regards	  to	  immune	  regulation	  has	  not	  been	  studied.	  This	  is	  of	  particular	  interest	  because	  of	  the	  well-­‐documented	  effect	  of	  immune	  suppression	  caused	  by	  the	  tumor	  that	  complicates	  and	  limits	  the	  effectiveness	  of	  treatments.	  	  
	   TUMOR	  IMMUNOLOGY	  Immune	  surveillance	  for	  cancerous	  cells	  is	  another	  important	  role	  of	  the	  immune	  system.	  The	  concept	  of	  immunoediting	  describes	  the	  balance	  between	  tumor	  elimination	  and	  tumor	  escape	  (Swann	  and	  Smyth,	  2007).	  Lymphocytes	  survey	  the	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brain	  for	  regular	  maintenance	  and	  homeostasis	  and	  tumor-­‐specific	  antigens	  can	  be	  recognized	  and	  eliminated	  (Engelhardt	  and	  Ransohoff,	  2005).	  In	  cases	  where	  tumor	  cells	  are	  not	  completely	  eliminated,	  a	  state	  of	  equilibrium	  can	  develop	  between	  the	  immune	  system	  and	  the	  developing	  tumor	  whereby	  the	  selective	  pressures	  of	  immune	  attack	  foster	  changes	  and	  evolvement	  of	  DNA	  mutations	  and	  tumor-­‐specific	  antigens.	  This	  can	  continue	  until	  the	  tumor	  cell	  variants	  are	  capable	  of	  resisting	  and	  suppressing	  the	  antitumor	  response	  (Swann	  and	  Smyth,	  2007).	  In	  this	  way,	  immunoediting	  can	  lead	  to	  the	  development	  of	  a	  tumor	  that	  will	  not	  be	  recognized	  and	  eliminated	  by	  the	  immune	  system.	  	  Immune	  suppression	  is	  another	  hallmark	  characteristic	  of	  glioblastomas	  and	  the	  degree	  of	  immune	  suppression	  positively	  correlates	  with	  tumor	  size	  (Morford	  et	  al.,	  1997).	  Despite	  studies	  demonstrating	  the	  presence	  of	  tumor	  infiltrating	  immune	  cell	  populations	  and	  the	  presence	  of	  glioma-­‐specific	  tumor	  antigens	  (Kurpad	  et	  al.,	  1995),	  cellular	  activation	  and	  immunological	  functions	  are	  reportedly	  attenuated	  in	  many	  aspects	  (Dix	  et	  al.,	  1999).	  Early	  observations	  of	  impaired	  cell-­‐mediated	  immunity	  in	  GBM	  patients	  include	  reduced	  and	  anergic	  T-­‐cells	  populations,	  reduced	  delayed-­‐type	  hypersensitivity	  responses	  to	  common	  antigens	  and	  abnormal	  proportions	  of	  helper	  and	  regulatory	  T-­‐cell	  subsets	  (Dix	  et	  al.,	  1999).	  These	  immune	  defects	  are	  attributed	  to	  tumor-­‐suppressive	  mechanisms	  since	  immune	  functions	  are	  restored	  following	  surgical	  resection	  of	  the	  tumor	  (Brooks	  et	  al.,	  1981).	  The	  decreased	  T-­‐cell	  counts	  could	  result	  from	  decreased	  proliferation	  following	  activation	  or	  cell	  death	  from	  tumor-­‐induced	  apoptosis.	  T-­‐cell	  fractions	  isolated	  from	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GBM	  patients	  were	  shown	  to	  be	  unresponsive	  to	  mitogen	  stimulation	  and	  unable	  to	  enter	  G1	  phase	  of	  the	  cell	  cycle	  (Elliott	  et	  al.,	  1984).	  Patient-­‐derived	  T-­‐cells	  also	  have	  signaling	  defects	  in	  interleukin-­‐2	  (IL-­‐2)	  production	  and	  secretion	  (Elliott	  et	  al.,	  1984).	  IL-­‐2	  is	  a	  cytokine	  involved	  in	  T	  cell	  proliferation	  and	  activation.	  Following	  antigen	  presentation	  and	  the	  co-­‐stimulatory	  signal,	  IL-­‐2	  and	  its	  receptor	  are	  transcriptional	  up-­‐regulated	  and	  begin	  signaling	  in	  an	  autocrine	  manner	  to	  increase	  proliferation.	  The	  reduced	  IL-­‐2	  production	  by	  T-­‐cells	  from	  GBM	  patients	  likely	  results	  from	  down-­‐regulation	  of	  IL-­‐2	  along	  with	  the	  IL-­‐2	  receptor	  since	  the	  addition	  of	  recombinant	  IL-­‐2	  to	  lymphocyte	  cultures	  did	  not	  restore	  proliferation	  defects	  (Elliott	  et	  al.,	  1984).	  This	  inability	  to	  produce	  and	  respond	  to	  IL-­‐2	  signaling	  results	  in	  T-­‐cell	  anergy.	  Along	  with	  T-­‐cell	  anergy,	  GBM	  patients	  were	  shown	  to	  have	  a	  higher	  percentage	  of	  apoptotic	  peripheral	  T-­‐cells	  and	  a	  separate	  study	  demonstrated	  that	  glioma	  cells	  can	  directly	  induce	  programmed	  cell	  death	  in	  T-­‐cells	  through	  the	  Fas-­‐ligand	  receptors	  (Morford	  et	  al.,	  1999).	  The	  Fas	  receptor	  is	  normally	  expressed	  by	  activated	  T-­‐cells	  following	  immune	  response.	  This	  is	  an	  important	  regulatory	  mechanism	  for	  preventing	  chronic	  inflammation	  and	  autoimmune	  disease.	  (Lynch	  et	  al.,	  1995).	  GBM	  cells	  advantageously	  express	  Fas-­‐ligand	  and	  its	  receptor	  and	  have	  been	  shown	  to	  induce	  apoptosis	  in	  Fas-­‐expressing	  T-­‐cells	  in	  culture	  (Saas	  et	  al.,	  1997).	  	  Additional	  mechanisms	  employed	  by	  the	  tumor	  that	  contribute	  to	  immune	  escape	  include	  the	  production	  of	  immunosuppressive	  cytokines	  IL-­‐10	  and	  TGF-­‐β,	  down-­‐regulation	  of	  MHC	  molecules	  and	  decreased	  co-­‐stimulatory	  signals	  from	  mediators	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of	  the	  antitumor	  immune	  response	  (Zou	  et	  al.,	  1999)	  (Bodmer	  et	  al.,	  1989)	  (Hussain	  et	  al.,	  2006).	  Microglia/macrophages	  are	  important	  contributors	  to	  the	  activation	  of	  adaptive	  immune	  responses	  through	  cytokine	  production	  along	  with	  antigen	  presentation	  and	  expression	  of	  the	  co-­‐stimulatory	  signals.	  Hussain	  et	  al.	  examined	  tumor-­‐infiltrating	  microglia/macrophages	  from	  GBM	  tumors	  and	  found	  that	  pro-­‐inflammatory	  cytokines	  expression	  levels	  were	  low	  or	  absent	  and	  they	  lacked	  co-­‐stimulatory	  molecules	  CD86,	  CD80	  and	  CD40	  necessary	  for	  T-­‐cell	  activation	  (Hussain	  et	  al.,	  2006).	  These	  findings	  suggest	  that	  GBMs	  can	  directly	  impair	  antitumor	  responses	  to	  avoid	  immune	  detection	  and	  promote	  tumor	  progression.	  	  Due	  to	  the	  variation	  between	  anti-­‐tumor	  immunity	  and	  adapted	  immune	  evasion	  by	  the	  tumor,	  it	  is	  important	  to	  study	  glioblastoma	  tumors	  obtained	  from	  long	  term	  glioblastoma	  survivors	  in	  order	  to	  understand	  the	  mechanisms	  resulting	  in	  successful	  tumor	  elimination.	  A	  study	  by	  Donson	  et	  al.	  examined	  high-­‐grade	  astrocytomas	  from	  long-­‐term	  survivors	  using	  gene	  expression	  microarray	  analysis	  to	  identify	  prognostic	  biomarkers	  associated	  with	  long-­‐term	  survival.	  They	  found	  that	  increased	  expression	  of	  immune	  function-­‐related	  genes	  was	  the	  predominant	  biological	  factor	  that	  positively	  correlated	  with	  longer	  survival.	  Gene	  sets	  associated	  with	  innate	  and	  adaptive	  immunity	  were	  highly	  expressed.	  A	  particularly	  large	  number	  of	  genes	  expressed	  by	  T	  cells	  (CD3D,	  CD3E,	  CD3G,	  CD8B,	  TRAC,	  TRAT1,	  VAV1,	  and	  ZAP70),	  microglia/macrophages	  (AIF1,	  CD68,	  CD86,	  CIITA,	  HLA-­‐DOA,	  HLA-­‐DQB2,	  HLA-­‐DRB1,	  HLA-­‐DRB6,	  NOD2),	  and	  also	  several	  toll-­‐like	  receptors	  (TLR	  2,	  3,	  5,	  6,	  7,	  8)	  were	  associated	  with	  long-­‐term	  survival.	  No	  positive	  immune-­‐related	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genes	  were	  found	  to	  be	  negatively	  correlated	  with	  survival.	  Furthermore,	  there	  were	  no	  negative	  immune	  regulators	  (TGF-­‐β,	  FOXP3,	  STAT3)	  associated	  with	  long-­‐term	  survival.	  However,	  the	  immunosuppressive	  cytokine	  IL-­‐4	  was	  found	  to	  be	  associated	  with	  shorter	  survival.	  Classifier	  gene	  sets	  for	  specific	  lymphoid	  lineages	  were	  made	  to	  identify	  important	  cell	  types.	  Genes	  designated	  as	  markers	  for	  CD4	  helper	  and	  CD8	  cytotoxic	  T	  cells	  and	  NK	  cells	  were	  significantly	  enriched,	  while	  myeloid	  lineage	  subsets	  approached	  significance.	  Histological	  analysis	  was	  also	  performed	  and	  demonstrated	  significant	  cytotoxic	  T-­‐cell	  infiltration	  within	  the	  tumors	  of	  long-­‐time	  survivors,	  while	  the	  proportion	  of	  microglia/microphage	  fraction	  approached	  significance	  (Donson	  et	  al.,	  2012).	  	  Immunotherapy	  attempts	  have	  been	  made	  to	  circumvent	  the	  immune	  suppressive	  mechanisms	  deployed	  by	  GBMs	  to	  elicit	  a	  more	  effective	  immune	  response	  against	  the	  tumor.	  Vaccination	  strategies	  using	  peptide-­‐pulsed	  dendritic	  cells	  have	  been	  attempted	  with	  some	  success	  to	  improve	  tumor	  antigen	  presentation	  (Yu	  et	  al.,	  2004).	  In	  this	  case,	  patient-­‐derived	  hematopoetic	  stem	  cells	  were	  isolated	  and	  expanded	  ex	  vivo	  into	  dendritic	  cells,	  cultured	  with	  surface	  peptides	  from	  the	  GBM	  tumors,	  and	  then	  used	  to	  vaccinate	  GBM	  patients.	  Follow	  up	  analysis	  found	  significant	  T-­‐cell	  cytotoxicity	  against	  autologous	  GBMs	  in	  four	  patients	  and	  two	  of	  four	  patients	  undergoing	  secondary	  tumor	  operation	  showed	  extensive	  cytotoxic	  and	  memory	  T-­‐cell	  infiltration	  of	  the	  tumor	  mass	  (Yu	  et	  al.,	  2004).	  Apetoh	  et	  al.	  found	  that	  the	  antitumor	  response	  and	  the	  cross	  presentation	  of	  tumor	  antigen	  by	  dendritic	  cells	  depends	  on	  TLR4	  and	  the	  release	  of	  the	  damage-­‐associated	  HMGB1	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protein	  from	  dying	  tumor	  cells	  as	  an	  immunogenic	  signal.	  This	  signaling	  is	  dependent	  on	  MyD88	  signaling	  and	  downstream	  NF-­‐κB	  activation	  (Apetoh	  et	  al.,	  2007).	  Curtin	  et	  al.	  followed	  up	  this	  finding	  by	  using	  adenoviral	  delivery	  system	  to	  introduce	  the	  Fms-­‐like	  tyrosine	  kinase	  3	  ligand	  (Flt3L)	  and	  thymidine	  kinase	  into	  the	  tumor	  microenvironment	  in	  order	  to	  activate	  dendritic	  cells	  and	  promote	  tumor	  cell	  necrosis,	  respectively.	  Using	  this	  therapy	  in	  a	  mouse	  model,	  they	  showed	  significant	  increase	  in	  survival	  that	  was	  accompanied	  by	  increased	  dendritic	  cell	  infiltration	  and	  dependent	  on	  CD4	  and	  CD8	  T-­‐cell	  activation.	  They	  confirmed	  that	  this	  antitumor	  response	  was	  due	  to	  the	  release	  of	  tumor	  HMGB1	  and	  dependent	  on	  TLR	  signaling	  (Curtin	  et	  al.,	  2009).	  
	   SUMMARY	  Cancer	  has	  been	  described	  as	  an	  aberrant	  wound	  in	  regards	  to	  structural	  composition	  and	  environmental	  conditions	  such	  as	  inflammation,	  hypoxia,	  and	  tissue	  necrosis.	  Similar	  to	  a	  wound	  repair	  response,	  tumor	  formation	  stimulates	  NSC	  proliferation	  and	  migration	  towards	  the	  tumor.	  This	  migration	  is	  mediated	  by	  factors	  derived	  from	  the	  tumor	  such	  as	  SDF-­‐1	  and	  HMGB1	  and	  also	  inflammatory	  cytokines	  from	  tumor-­‐infiltrating	  macrophages.	  The	  interactions	  that	  take	  place	  between	  NSCs	  and	  GBM	  cells	  within	  the	  tumor	  microenvironment	  are	  unknown	  but	  can	  result	  in	  reduced	  tumor	  growth	  and	  increased	  survival	  in	  mice	  models.	  The	  expression	  of	  TLR2	  and	  TLR4	  by	  NSCs	  could	  allow	  a	  mechanism	  for	  GBM	  recognition	  considering	  that	  GBMs	  release	  the	  HMGB1	  protein	  that	  binds	  and	  activates	  these	  receptors.	  TLR	  signaling	  leads	  to	  downstream	  NF-­‐κB	  activation	  and	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OBJECTIVES	  AND	  HYPOTHESES	  	  	  	  
The	  objective	  of	  this	  project	  was	  to	  study	  the	  mode	  and	  mechanism	  of	  NSC-­‐
mediated	  tumor	  suppression.	  Many	  studies	  have	  characterized	  the	  migration	  of	  NSCs	  towards	  glioblastoma	  tumors	  and	  there	  is	  reported	  evidence	  on	  their	  tumor-­‐suppressive	  properties.	  However,	  the	  mode	  and	  mechanism	  behind	  this	  anti-­‐tumor	  response	  is	  not	  well	  understood.	  This	  interaction	  could	  be	  contact-­‐dependent	  or	  mediated	  through	  releasable	  factors	  and/or	  microvesicles.	  In	  this	  study,	  the	  mode	  of	  NSC-­‐mediated	  tumor	  suppression	  was	  determined	  by	  measuring	  the	  proliferation	  of	  GBM	  cells	  co-­‐cultured	  with	  NSCs	  using	  a	  transwell	  system	  that	  separates	  the	  two	  cell	  types	  but	  allows	  for	  intercellular	  communication	  through	  releasable	  factors.	  Reduced	  GBM	  proliferation	  following	  NSC	  co-­‐culture	  using	  this	  system	  indicates	  that	  there	  are	  factors	  produced	  by	  the	  NSCs	  that	  influence	  GBM	  proliferation	  and/or	  viability.	  Potential	  targets	  include	  factors	  of	  the	  tumor	  necrosis	  factor	  super	  family	  that	  are	  commonly	  involved	  in	  inducing	  programmed	  cell	  death.	  Gene	  expression	  analysis	  of	  these	  suspected	  targets	  was	  performed	  with	  RT-­‐PCR	  on	  NSCs	  following	  GBM	  co-­‐culture.	  Furthermore,	  the	  mechanism	  underlying	  this	  suppressive	  effect	  will	  be	  determined	  by	  examining	  GBM	  gene	  expression	  changes	  related	  to	  stress	  response,	  apoptosis	  and	  survival	  genes.	  Because	  these	  anti-­‐tumor	  properties	  of	  NSCs	  could	  be	  influenced	  by	  the	  conditions	  of	  the	  tumor	  microenvironment	  such	  as	  hypoxia,	  the	  co-­‐culture	  proliferation	  assays	  and	  the	  gene	  expression	  analysis	  will	  be	  performed	  under	  both	  normoxic	  and	  hypoxic	  conditions.	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Hypothesis	  1:	  NSCs	  can	  directly	  suppress	  tumor	  proliferation	  through	  releasable	  factors	  and	  this	  suppression	  is	  influenced	  by	  the	  conditions	  of	  the	  tumor	  microenvironment.	  
(Aim	  1a)	  Measure	  GBM	  proliferation	  following	  co-­‐culture	  with	  NSCs	  in	  a	  transwell	  system	  under	  normal	  and	  hypoxic	  conditions.	  (1b)	  Examine	  GBM	  gene	  expression	  changes	  related	  to	  apoptotic/anti-­‐apoptotic	  and	  stress	  response	  genes	  following	  NSC	  co-­‐culture.	  (1c)	  Examine	  NSC	  gene	  expression	  changes	  related	  to	  TNF	  death	  receptor	  ligand	  signaling.	  	  Another	  important	  consideration	  is	  an	  indirect	  mode	  of	  NSC-­‐mediated	  tumor	  suppression	  that	  could	  potentially	  involve	  immune	  signaling	  and	  the	  activation	  of	  anti-­‐tumor	  immune	  responses.	  NSCs	  migration	  appears	  to	  reflect	  a	  wound	  repair	  response	  and	  NSCs	  have	  been	  shown	  to	  participate	  in	  immune	  signaling.	  Since	  immune	  suppression	  is	  a	  common	  mechanism	  of	  tumor	  progression,	  we	  propose	  that	  NSC-­‐mediated	  tumor	  suppression	  involves	  a	  process	  comparable	  to	  wound	  repair	  that	  involves	  immune	  cell	  recruitment	  and	  activation	  that	  could	  subsequently	  result	  in	  an	  anti-­‐tumor	  immune	  response.	  Gene	  expression	  analysis	  of	  immune-­‐related	  genes	  following	  co-­‐culture	  with	  GBM	  cells	  will	  provide	  insight	  into	  the	  potential	  immune	  contributions	  of	  NSCs.	  	  	  
Hypothesis	  2:	  NSCs	  can	  indirectly	  mediate	  tumor	  suppression	  through	  immune	  signaling.	  (Aim	  2)	  Examine	  NSC	  gene	  expression	  changes	  related	  to	  immune	  response/cytokine	  genes	  following	  co-­‐culture	  with	  GBMs.	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METHODS	  	  	  	  CELL	  CULTURE	  Mouse	  glioblastoma	  cell	  line	  GL261	  was	  maintained	  in	  DMEM	  with	  10%	  FBS	  at	  37	  degrees	  and	  5%	  CO2	  in	  normal	  humidified	  conditions.	  Mouse	  embryonic	  neural	  stem	  cells	  (NSCs)	  were	  purchased	  from	  Stem	  Cell	  Technologies	  (Cat.	  #00330).	  NSCs	  were	  initially	  started	  as	  suspended	  neurosphere	  cultures	  at	  5x106	  cells/20mL	  in	  a	  T-­‐75	  cm2	  flask	  using	  Neurocult	  proliferation	  media	  (StemCell	  Tech,	  Cat.	  #05702)	  supplemented	  with	  EGF	  (Peprotech,	  20	  ng/ml)	  (referred	  to	  as	  stem	  cell	  media).	  NSC	  cultures	  were	  converted	  to	  monolayers	  once	  the	  neurospheres	  reached	  approximately	  150-­‐200μm	  in	  diameter.	  Accutase	  (StemCell	  Tech,	  Cat.	  #07920)	  was	  used	  for	  dissociation	  and	  cells	  were	  then	  plated	  on	  plates	  coated	  with	  a	  combination	  of	  poly-­‐D-­‐lysine	  (PDL,	  Sigma	  P7280)	  and	  laminin	  (Sigma	  L2020).	  Prior	  to	  plating,	  monolayer	  plates	  were	  prepared	  accordingly:	  PDL	  was	  first	  added	  to	  a	  normal	  tissue	  culture	  6-­‐well	  plate	  at	  100μg/ml	  for	  2	  hours	  at	  37	  degrees.	  PDL	  was	  removed	  and	  the	  flask	  was	  washed	  once	  with	  PBS	  before	  adding	  laminin	  at	  10μg/ml	  for	  2-­‐hours	  at	  37	  degrees.	  Coated	  plates	  were	  prepared	  new	  each	  time	  the	  NSCs	  were	  passaged.	  NSC	  monolayers	  were	  initially	  plated	  at	  8x104	  cells/cm2	  in	  3ml/well	  until	  reaching	  60-­‐80%	  confluency.	  At	  that	  point	  the	  NSCs	  were	  dissociated	  and	  replated	  at	  2x104	  cells/cm2	  in	  a	  newly	  coated	  6-­‐well	  plate.	  	  Co-­‐cultures	  were	  setup	  using	  24-­‐well	  transwell	  inserts	  (Greiner	  Bio-­‐one,	  cat.	  #662610).	  GL261s	  were	  first	  plated	  in	  the	  24-­‐well	  plate	  at	  50,000	  cells/well	  in	  1ml	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of	  DMEM	  with	  10%	  FBS.	  The	  NSCs	  were	  initially	  plated	  in	  a	  separate	  plate	  inside	  the	  transwell	  inserts	  at	  25,000	  cells/well	  in	  200ul	  of	  Neurocult	  media	  with	  EGF.	  The	  cells	  from	  each	  plate	  were	  then	  incubated	  and	  allowed	  to	  resume	  growth	  overnight.	  	  On	  the	  following	  day	  the	  co-­‐cultures	  were	  setup	  by	  first	  washing	  each	  well	  and	  insert	  once	  with	  PBS.	  The	  NSC	  inserts	  were	  then	  placed	  inside	  the	  wells	  containing	  the	  GL261	  cells	  and	  then	  Neurocult	  with	  EGF	  media	  was	  added	  to	  the	  wells	  to	  make	  a	  2:1	  co-­‐culture.	  GL261	  proliferation	  was	  compared	  between	  the	  DMEM	  with	  FBS	  and	  the	  neurocult	  with	  EGF	  (Supplemental	  figure	  1).	  	   PROLIFERATION	  ASSAY	  GL261	  proliferation	  was	  measured	  using	  the	  alamarblue	  viability	  assay	  (Life	  technologies	  Cat.	  #DAL1025).	  Cell	  number	  was	  measured	  over	  the	  duration	  of	  72	  hours	  at	  24-­‐hour	  intervals.	  A	  plate	  was	  prepared	  with	  all	  of	  the	  controls,	  another	  plate	  for	  all	  the	  normoxic	  co-­‐cultures	  and	  separate	  plates	  for	  the	  hypoxic	  co-­‐cultures.	  Each	  designated	  time	  point	  had	  3	  co-­‐culture	  wells.	  The	  normoxic	  co-­‐culture	  plates	  were	  prepared	  with	  one	  column	  (three	  wells)	  containing	  blank	  wells	  with	  only	  neurocult	  media	  for	  blanking	  the	  spectrometer	  and	  then	  four	  following	  columns	  for	  the	  T0,	  24,	  48,	  72	  time	  points	  (three	  co-­‐cultures	  each).	  The	  hypoxic	  plate	  was	  prepared	  with	  each	  time	  point	  on	  a	  separate	  plate	  (control	  and	  co-­‐culture).	  This	  was	  done	  to	  not	  disturb	  the	  other	  time	  points	  when	  moving	  the	  plate	  to	  normoxia	  for	  alamarblue	  addition	  and	  incubation.	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At	  each	  measuring	  interval	  the	  co-­‐culture	  was	  disassembled	  by	  removing	  the	  transwell	  insert	  and	  removing	  the	  used	  media.	  This	  conditioned	  media	  was	  saved	  for	  future	  analysis.	  New	  media	  was	  added	  along	  with	  10%	  alamarblue	  reagent.	  Once	  the	  alamarblue	  was	  added	  the	  plate	  was	  incubated	  for	  6	  hours	  in	  normoxia	  to	  allow	  for	  metabolic	  reduction	  of	  the	  reagent	  and	  colorimetric	  change.	  This	  incubation	  duration	  was	  predetermined	  experimentally	  (Supplemental	  figure	  2)	  because	  the	  proper	  duration	  varies	  with	  each	  cell	  type	  and	  cell	  density.	  After	  the	  6-­‐hour	  incubation	  a	  100ul	  sample	  from	  each	  well	  was	  transferred	  to	  a	  96-­‐well	  plate	  for	  reading	  with	  the	  spectrometer.	  	  Alamarblue	  is	  a	  metabolic	  indicator	  that	  becomes	  reduced	  during	  cellular	  respiration	  and	  undergoes	  a	  colorimetric	  change	  from	  a	  blue	  oxidized	  form	  to	  a	  red	  reduced	  form.	  Based	  on	  its	  reduction	  potential,	  it	  is	  an	  intermediate	  between	  the	  cytochromes	  of	  the	  electron	  transport	  chain	  and	  the	  final	  reduction	  of	  oxygen.	  Therefore,	  it	  does	  not	  disrupt	  the	  flow	  of	  electrons	  and	  is	  nontoxic	  to	  cell	  culture,	  in	  contrast	  to	  MTT,	  which	  has	  a	  reduction	  potential	  lower	  than	  the	  cytochromes.	  	  	  Absorbance	  was	  monitored	  at	  570nm	  (reduced)	  and	  600nm	  (oxidized)	  with	  the	  spectrometer	  and	  the	  percent	  reduction	  from	  the	  blue	  oxidized	  form	  was	  computed	  using	  the	  equation	  below.	  Relative	  percent	  reduction	  numbers	  were	  calculated	  by	  subtracting	  the	  baseline	  percent	  reduction	  at	  T0	  from	  the	  following	  time	  points.	  Statistical	  analysis	  was	  performed	  using	  the	  student	  t-­‐test	  to	  compare	  the	  relative	  percent	  reduction	  at	  each	  time	  point	  between	  groups.	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   REAL-­‐TIME	  PCR	  Gene	  expression	  analysis	  was	  performed	  on	  the	  NSCs	  and	  the	  GL261s	  following	  co-­‐culture	  for	  72	  hours	  using	  the	  RT2	  Profiler	  PCR	  array	  (Qiagen	  PAMM-­‐225Z).	  This	  array	  includes	  a	  panel	  of	  96	  target	  genes	  of	  the	  NF-­‐κB	  pathway	  including	  housekeeping	  genes	  for	  normalizing	  the	  data	  (Supplemental	  table	  1).	  The	  housekeeping	  genes	  include	  actin-­‐beta	  (Actb),	  beta-­‐2	  microglobulin	  (B2m),	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  (Gapdh),	  glucuronidase-­‐beta	  (Gusb),	  and	  heat	  shock	  protein	  90-­‐alpha	  (Hsp90ab1).	  	  Separate	  plates	  for	  RNA	  collection	  were	  prepared	  for	  the	  normoxic	  controls	  and	  co-­‐cultures	  and	  the	  hypoxic	  controls	  and	  co-­‐cultures.	  Twenty	  (20)	  wells	  were	  setup	  for	  each	  plate.	  After	  the	  72-­‐hour	  time	  point	  the	  co-­‐cultures	  were	  disassembled	  and	  the	  cells	  were	  lysed	  with	  RLT	  buffer	  and	  the	  lysates	  were	  consolidated	  for	  RNA	  purification	  and	  first	  strand	  synthesis.	  RNA	  was	  purified	  using	  the	  RNeasy	  mini	  kit	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(Qiagen	  Cat.	  #74104).	  cDNA	  was	  synthesized	  using	  the	  RT2	  first	  strand	  kit	  that	  included	  a	  genomic	  DNA	  elimination	  mix	  and	  the	  reverse	  transcription	  mix	  with	  the	  RE3	  enzyme.	  	  The	  real-­‐time	  PCR	  reaction	  was	  performed	  using	  the	  RT2	  SYBR	  green	  mastermix	  (Qiagen	  #330512).	  The	  PCR	  mix	  was	  loaded	  into	  the	  array	  plate	  using	  an	  8-­‐channel	  micropipettor	  and	  the	  reaction	  was	  started	  using	  the	  MyiQ	  real-­‐time	  PCR	  thermocycler.	  The	  cycler	  was	  programmed	  to	  begin	  with	  1	  cycle	  at	  95°C	  for	  10	  min	  to	  activate	  the	  HotStart	  DNA	  Taq	  Polymerase	  and	  then	  40	  cycles	  starting	  at	  95°C	  for	  15	  seconds	  and	  decreasing	  to	  60°C	  for	  1	  min.	  The	  threshold	  cycle	  (Ct)	  was	  calculated	  by	  choosing	  the	  automatic	  baseline	  option	  and	  then	  setting	  the	  threshold	  value	  to	  10	  from	  the	  log	  view	  amplification	  plot.	  The	  Ct	  values	  were	  then	  exported	  to	  Excel	  and	  analyzed	  using	  the	  SABiosciences	  web-­‐based	  software.	  Gene	  expression	  was	  analyzed	  using	  the	  comparative	  Ct	  method	  (Schmittgen	  and	  Livak,	  2008).	  This	  involved	  comparing	  the	  Ct	  values	  from	  the	  co-­‐cultured	  cells	  to	  the	  controls	  after	  normalization	  to	  B2m,	  Gusb,	  and	  Hsp90ab1.	  Fold	  change	  (2^(-­‐delta	  delta	  Ct))	  is	  the	  normalized	  gene	  expression	  (2^(-­‐delta	  Ct))	  in	  the	  test	  sample	  divided	  by	  the	  normalized	  gene	  expression	  (2^(-­‐delta	  Ct))	  in	  the	  control	  sample.	  Fold	  change	  values	  greater	  than	  one	  indicate	  a	  positive	  up-­‐regulation	  and	  the	  fold	  regulation	  is	  equal	  to	  the	  fold	  change.	  Fold	  change	  values	  less	  than	  one	  indicate	  a	  negative	  down-­‐regulation	  and	  the	  fold	  regulation	  is	  the	  negative	  inverse	  of	  the	  fold	  change.	  This	  method	  was	  used	  to	  examine	  gene	  expression	  changes	  between	  the	  co-­‐culture	  and	  control	  groups	  under	  normoxia	  and	  hypoxia	  for	  GL261s	  and	  NSCs.	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RESULTS	  	  	  	  NEURAL	  STEM	  CELLS	  SUPPRESS	  GL261	  PROLIFERATION	  UNDER	  NORMAL	  BUT	  NOT	  HYPOXIC	  CONDITIONS	  The	  cellular	  interactions	  between	  NSCs	  and	  GL261	  glioma	  cells	  were	  studied	  using	  an	  in	  vitro	  transwell	  co-­‐culturing	  system	  that	  separates	  the	  two	  cell	  types	  but	  allows	  for	  intercellular	  communication	  via	  releasable	  factors	  transmitted	  through	  the	  semi-­‐permeable	  insert.	  GL261s	  were	  plated	  at	  50,000	  cells/well	  in	  a	  24-­‐well	  plate	  and	  NSCs	  were	  added	  to	  the	  insert	  at	  25,000	  cells/well	  for	  a	  2:1	  co-­‐culture.	  GL261	  proliferation	  was	  measured	  over	  the	  course	  of	  72	  hours	  at	  24-­‐hour	  intervals	  using	  the	  alamarblue	  assay	  to	  determine	  the	  metabolic	  activity	  in	  correlation	  with	  cell	  number.	  Reduction	  of	  the	  metabolic	  indicator	  causes	  a	  colorimetric	  change	  that	  can	  be	  measured	  from	  the	  absorbance	  and	  then	  converted	  to	  percent	  reduction.	  A	  higher	  percent	  reduction	  therefore	  indicates	  a	  higher	  metabolic	  activity	  and	  more	  proliferation	  in	  the	  culture.	  	  Under	  normoxic	  conditions	  there	  was	  a	  significant	  decrease	  in	  the	  reduction	  of	  alamarblue	  by	  the	  GL261s	  co-­‐cultured	  with	  NSCs	  compared	  to	  the	  normoxic	  control,	  indicating	  a	  decrease	  in	  proliferation	  and/or	  cell	  survival	  (Figure	  1).	  The	  percent	  reduction	  difference	  between	  the	  co-­‐culture	  and	  the	  control	  was	  5.4	  percent	  (p=0.001)	  after	  48	  hours	  and	  6.8	  percent	  (p=0.005)	  after	  72	  hours.	  Furthermore,	  the	  density	  of	  GL261	  cells	  was	  decreased	  in	  the	  area	  directly	  below	  the	  NSC	  insert	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compared	  to	  the	  outside	  perimeter,	  based	  on	  visual	  observation,	  suggesting	  either	  cell	  death	  or	  migration	  away	  from	  the	  NSCs	  (no	  data	  shown).	  	  The	  proliferation	  assay	  was	  also	  performed	  under	  hypoxia	  to	  represent	  the	  conditions	  of	  the	  tumor	  microenvironment	  (Figure	  2).	  In	  contrast	  to	  the	  normoxic	  co-­‐culture,	  GL261	  proliferation	  was	  not	  affected	  by	  the	  NSCs	  under	  these	  conditions.	  This	  suggests	  that	  either	  hypoxia	  affects	  the	  survival	  of	  GL261s	  or	  that	  NSCs	  respond	  differently	  under	  hypoxic	  conditions.	  	  When	  we	  compared	  the	  proliferation	  of	  the	  GL261	  hypoxic	  control	  to	  the	  normoxic	  control,	  we	  found	  that	  proliferation	  under	  hypoxia	  was	  comparable	  to	  the	  normoxic	  group	  throughout	  the	  first	  48	  hours	  but	  then	  decreased	  after	  72	  hours	  (p=0.0003)	  (Figure	  3).	  The	  relatively	  normal	  proliferation	  rate	  throughout	  the	  first	  48	  hours	  under	  hypoxia	  might	  suggest	  increased	  survival	  mechanisms	  that	  could	  counteract	  the	  stresses	  of	  hypoxia.	  Many	  survival	  mechanisms	  implicated	  in	  cancer	  progression	  have	  been	  attributed	  to	  hypoxia	  (Harris,	  2002).	  Furthermore,	  the	  reduced	  proliferation	  rate	  between	  48-­‐72	  hours	  could	  have	  minimized	  the	  suppressive	  effect	  observed	  from	  the	  NSCs.	  Overall	  this	  data	  shows	  that	  NSCs	  can	  directly	  suppress	  GL261	  proliferation	  in	  a	  contact-­‐independent	  mechanism	  under	  normoxic	  but	  not	  hypoxic	  conditions.	  Further	  analysis	  is	  required	  to	  determine	  the	  mechanism	  of	  this	  NSC-­‐mediated	  suppression.	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GL261	  Proliferation	  (Normoxic	  co-­‐culture)	  



















GL261	  Proliferation	  (Hypoxic	  co-­‐culture)	  
HPX	  control	  HPX/NSCs	  
Figure	  1:	  GL261	  cell	  proliferation	  measured	  by	  alamarblue	  reduction	  following	  2:1	  co-­‐culture	  with	  NSCs	  in	  transwell	  system.	  Relative	  percent	  reduction	  equals	  the	  difference	  in	  reduction	  between	  each	  time	  point	  and	  time	  zero.	  NMX	  represents	  the	  normoxic	  group	  and	  the	  asterisks	  indicate	  statistical	  significance	  (<0.05).	  
Figure 2: GL261 cell proliferation measured by alamarblue reduction under hypoxic conditions 
following 2:1 co-culture with NSCs in transwell system. HPX represents the hypoxic group. 
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GL261	  Proliferation	  (Normoxic/Hypoxic)	  
NMX	  HPX	  
Figure 3: GL261 cell proliferation measured by alamarblue reduction under normoxic and hypoxic 
conditions. These groups represent the controls for each co-culture experiment. 
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GL261	  gene	  expression-­‐	  NMX	  co-­‐culture	  (NMX)	  
Gene	   Function	   Fold	  Regulation	  Map2k6	   Apoptosis-­‐	  activation	  of	  p38-­‐MAPK	  pathway	   5.3	  Bcl2	   Survival-­‐	  negatively	  regulates	  BH123	  apoptotic	  proteins	   -­‐9.0	  
	  	  
GL261	  gene	  expression-­‐HPX	  co-­‐culture	  (HPX)	  
Gene	   Function	   Fold	  Regulation	  Adm	   Survival/proliferation	   4.1	  Bcl2	   Survival-­‐	  negatively	  regulates	  BH123	  apoptotic	  proteins	   2.7	  Gadd45b	   Survival-­‐	  negatively	  regulates	  JNK	  activation	   2.4	  Tnfsf6	  (Fasl)	   Death	  receptor	  ligand	   3.5	  









	   Trp53	   Adm	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   Bcl-­‐X	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Normalized	  GL261	  gene	  expression	  
Apoptosis/Survival	  
NMX	  coculture	  HPX	  coculture	  
Figure	  4:	  Gene	  expression	  changes	  represented	  by	  fold	  change	  relative	  to	  corresponding	  controls.	  The	  NMX	  co-­‐culture	  changes	  are	  relative	  to	  the	  normoxic	  control	  and	  HPX	  co-­‐cultures	  changes	  are	  relative	  to	  the	  hypoxic	  control.	  Genes	  1-­‐4	  are	  characterized	  as	  pro-­‐apoptotic	  and	  genes	  5-­‐13	  are	  characterized	  as	  survival	  or	  anti-­‐apoptotic.	  
Table 1: Gene expression analysis of RT-PCR data from GL261 cells co-cultured with NSCs under 
normoxic conditions. Expression changes are relative to the normoxic (NMX) control. Fold regulation was 
calculated as the inverse of fold change for negative values.  
Table 2: Gene expression analysis of RT-PCR data from GL261 cells co-cultured with NSCs under 
hypoxic conditions. Expression changes are relative to hypoxic (HPX) control. 
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The	  mitogen-­‐activated	  protein	  kinase	  (MAP2k6)	  that	  is	  involved	  in	  activating	  pro-­‐apoptotic	  p38-­‐MAPK	  was	  found	  to	  be	  up-­‐regulated	  5.3	  fold	  and	  anti-­‐apoptotic	  gene	  Bcl2	  involved	  in	  mitochondrial	  stability	  was	  down-­‐regulated	  0.11	  fold	  or	  -­‐9	  fold-­‐regulation	  in	  the	  normoxic	  co-­‐culture	  relative	  to	  the	  normoxic	  control	  (Figure	  4,	  Table	  1).	  This	  gene	  expression	  data	  corresponds	  with	  the	  decreased	  GL261	  proliferation	  data	  from	  the	  normoxic	  co-­‐culture	  (Figure	  1).	  The	  addition	  of	  hypoxia	  to	  the	  co-­‐culture	  had	  opposite	  effects	  on	  GL261	  cell	  proliferation	  and	  also	  gene	  expression	  levels	  of	  survival	  and	  pro-­‐apoptotic	  genes	  (Table	  2).	  We	  found	  a	  4-­‐fold	  increase	  in	  adrenomedullin	  (Adm)	  expression	  in	  the	  hypoxic	  co-­‐culture	  compared	  to	  the	  hypoxic	  control.	  Adm	  is	  a	  multifunctional	  pro-­‐survival	  gene	  with	  mitogenic	  and	  angiogenic	  functions	  in	  glioblastomas	  and	  has	  been	  shown	  to	  be	  regulated	  by	  hypoxia	  (Larrayoz	  et	  al.,	  2014).	  Our	  data	  supported	  these	  previous	  findings;	  Adm	  was	  also	  found	  up-­‐regulated	  8.1	  fold	  in	  the	  hypoxic	  control	  relative	  to	  the	  normoxic	  control	  (Table	  3),	  confirming	  that	  hypoxia	  alone	  can	  regulate	  Adm	  expression	  in	  GL261	  cells.	  However,	  the	  increased	  Adm	  expression	  in	  the	  hypoxic	  co-­‐culture	  was	  relative	  to	  the	  normally	  high	  expression	  of	  the	  hypoxic	  control,	  suggesting	  that	  the	  interactions	  of	  NSCs	  can	  further	  increase	  this	  pathway.	  	  In	  contrast	  to	  the	  normoxic	  co-­‐culture,	  Bcl2	  was	  found	  to	  be	  up-­‐regulated	  in	  the	  hypoxic	  co-­‐culture.	  However,	  this	  up-­‐regulation	  was	  relative	  to	  the	  hypoxic	  control	  where	  Bcl2	  was	  found	  to	  be	  down-­‐regulated	  by	  hypoxia	  (Tables	  2-­‐3).	  This	  down-­‐regulation	  of	  anti-­‐apoptotic	  Bcl2	  correlates	  with	  the	  decreased	  proliferation	  rate	  in	  the	  hypoxic	  control	  after	  72	  hours	  (Figure	  3).	  Tumor	  necrosis	  factor-­‐6	  (Fas-­‐ligand)	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that	  is	  involved	  in	  mediating	  programmed	  cell	  death	  upon	  binding	  to	  its	  receptor	  on	  the	  target	  cell	  was	  up-­‐regulated	  relative	  to	  the	  hypoxic	  control	  (3.5-­‐fold),	  along	  with	  Growth	  arrest	  and	  DNA	  damage-­‐inducible	  protein	  (Gadd45b).	  Gadd45b	  has	  been	  shown	  to	  block	  apoptosis	  by	  negatively	  regulating	  TNF-­‐induced	  JNK	  signaling	  (De	  Smaele	  et	  al.,	  2001).	  These	  finding	  correspond	  with	  the	  increased	  proliferation	  and/or	  survival	  of	  GL261s	  in	  hypoxic	  co-­‐culture	  compared	  to	  the	  normoxic	  co-­‐culture	  (Figures	  1-­‐2).	  
	  Taking	  together	  the	  proliferation	  data	  and	  the	  gene	  expression	  data	  from	  the	  normoxic	  NSC	  co-­‐culture,	  we	  show	  that	  there	  is	  a	  correlation	  between	  the	  decreased	  GL261	  proliferation	  rate	  and	  the	  increase	  in	  the	  pro-­‐apoptotic	  Map2k6	  and	  decrease	  in	  the	  Bcl2	  anti-­‐apoptotic	  pathways.	  The	  addition	  of	  hypoxia	  to	  the	  co-­‐culture	  prevented	  the	  NSC-­‐mediated	  suppression	  of	  GL261	  proliferation	  while	  also	  up-­‐regulating	  survival	  pathways.	  	  	   NEURAL	  STEM	  CELLS	  UP-­‐REGULATE	  TUMOR	  NECROSIS	  FACTORS	  NSC	  gene	  expression	  was	  also	  examined	  to	  determine	  how	  the	  NSCs	  respond	  to	  interacting	  with	  the	  glioma	  cells	  and	  to	  determine	  the	  underlying	  mechanism	  of	  GL261	  suppression.	  The	  genes	  selected	  for	  examination	  included	  NF-­‐κB	  target	  genes	  
GL261	  gene	  expression-­‐HPX	  (NMX)	  
Gene	   Function	   Fold	  Regulation	  Adm	   Survival/proliferation	   8.1	  Gadd45b	   Survival-­‐	  negatively	  regulates	  JNK	  activation	   1.5	  Bcl2	   Survival-­‐	  negatively	  regulates	  BH123	  apoptotic	  proteins	   -­‐16.4	  
Table 3: Gene expression analysis of RT-PCR data from GL261 cells cultured alone under hypoxic 
conditions. Expression changes are relative to normoxic (NMX) control. 
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related	  to	  tumor	  necrosis	  factor	  super	  family	  ligands,	  cytokines/chemokines	  and	  immune-­‐related	  genes	  involved	  with	  innate	  and	  adaptive	  immune	  responses.	  Real-­‐time	  PCR	  was	  performed	  on	  NSC	  lysates	  following	  the	  72-­‐hour	  co-­‐culture	  with	  GL261	  cells	  under	  either	  normal	  or	  hypoxic	  conditions.	  Gene	  expression	  comparisons	  were	  made	  relative	  to	  control	  cultures	  consisting	  of	  only	  NSCs	  under	  the	  same	  conditions.	  	  
	  
	  	  
NSC	  gene	  expression-­‐NMX	  co-­‐culture	  (NMX)	  
Gene	   Function	   Fold	  Regulation	  Tnfα	   Death	  receptor	  ligand,	  pro-­‐inflammatory	  cytokine	   3.2	  















Normalized	  NSC	  gene	  expression	  
Tnfsf	  ligands	  
NMX	  coculture	  HPX	  coculture	  
NSC	  gene	  expression-­‐HPX	  co-­‐culture	  (HPX)	  
Gene	   Function	   Fold	  Regulation	  
Tnfsf6	  (Fasl)	   Death	  receptor	  ligand	   4	  
Figure 5: Gene	  expression	  changes	  represented	  by	  fold	  change	  relative	  to	  corresponding	  control.	  The	  NMX	  co-­‐culture	  changes	  are	  relative	  to	  the	  normoxic	  (NMX)	  control	  and	  HPX	  co-­‐cultures	  changes	  are	  relative	  to	  the	  hypoxic	  (HPX)	  control. 
Table 4: Gene expression analysis of RT-PCR data from NSCs co-cultured with GL261s under 
normoxic conditions. Changes are relative to normoxic control group. 
 
Table 5: Gene expression analysis of RT-PCR data from NSCs co-cultured with GL261s under 
hypoxic conditions. Changes are relative to hypoxic control group. 
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Members	  of	  the	  tumor	  necrosis	  super	  family	  were	  examined	  in	  search	  of	  a	  mechanism	  behind	  NSC-­‐mediated	  GL261	  suppression.	  These	  mediators	  are	  known	  to	  regulate	  inflammatory	  processes	  and	  also	  apoptosis	  pathways	  through	  TNF	  super	  family	  receptors.	  Interestingly,	  NSCs	  had	  up-­‐regulated	  TNFα	  expression	  in	  the	  normoxic	  co-­‐culture	  and	  up-­‐regulated	  Tnfsf6	  (Fas-­‐ligand)	  in	  the	  normoxic	  and	  hypoxic	  co-­‐culture	  (Tables	  4-­‐5).	  	  These	  genes	  were	  not	  influenced	  by	  hypoxia	  alone,	  but	  only	  upon	  interactions	  with	  the	  GL261	  cells.	  	   NEURAL	  STEM	  CELLS	  IN	  IMMUNE	  SIGNALING	  We	  then	  examined	  the	  expression	  of	  genes	  involved	  in	  immune	  cell	  signaling	  to	  determine	  if	  NSCs	  can	  initiate	  immune	  cell	  recruitment	  following	  glioma	  cell	  interactions	  (Figure	  6).	  We	  found	  that	  NSCs	  co-­‐cultured	  with	  GL261s	  under	  both	  normoxic	  and	  hypoxic	  conditions	  showed	  a	  similar	  increase	  in	  the	  expression	  of	  multiple	  chemokines	  with	  the	  CXC	  motif	  including	  CXCL1	  and	  CXCL10	  along	  with	  the	  C-­‐C	  motif	  ligands	  CCL5	  (RANTES)	  and	  CCL12.	  Cell	  adhesion	  molecules	  Icam1	  and	  Vcam1	  that	  are	  important	  in	  cellular	  migration	  and	  invasion	  were	  also	  commonly	  up-­‐regulated	  in	  the	  NSCs	  (Tables	  6-­‐7).	  Specific	  changes	  to	  the	  normoxic	  co-­‐culture	  group	  included	  the	  up-­‐regulation	  of	  chemokines	  CXCL3	  and	  CXCL9	  whereas	  the	  hypoxic	  co-­‐culture	  group	  specifically	  up-­‐regulated	  CCR5.	  This	  data	  indicates	  that	  NSCs	  are	  involved	  in	  immune	  signaling	  by	  producing	  chemokines	  that	  are	  known	  to	  recruit	  innate	  and	  adaptive	  immune	  cells	  during	  wound	  repair.	  It	  also	  shows	  that	  this	  immune	  signaling	  is	  less	  influenced	  by	  hypoxia	  and	  more	  influenced	  by	  the	  interactions	  with	  GL261	  cells	  and	  the	  factors	  they	  release.	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Normalized	  NSC	  gene	  expression	  
Cytokines/Chemokines	  
NMX	  coculture	  HPX	  coculture	  
NSC	  gene	  expression-­‐	  NMX	  co-­‐culture	  (NMX)	  
Gene	   Function	  (Cytokines/Chemokines)	   Fold	  Regulation	  
CCL5	   Chemokine	   8	  
CCL12	   Chemokine	   2.6	  
Csf1	   Chemokine	   3.6	  
CXCL1	   Chemokine	   7.2	  
CXCL10	   Chemokine	   14	  CXCL3	   Chemokine	   5.1	  CXCL9	   Chemokine	   8.7	  
Icam1	   Adhesion	  molecule	   7.1	  
Vcam1	   Adhesion	  molecule	   5.1	  
Figure 6: Gene	  expression	  changes	  represented	  by	  fold	  change	  relative	  to	  corresponding	  control.	  The	  NMX	  co-­‐culture	  changes	  are	  relative	  to	  the	  normoxic	  (NMX)	  control	  and	  HPX	  co-­‐cultures	  changes	  are	  relative	  to	  the	  hypoxic	  (HPX)	  control. 
 
Table 6: Gene expression analysis of RT-PCR data from NSCs co-cultured with GL261s 
under normoxic conditions. Changes are relative to normoxic control group. Bold names 
indicate genes that are similarly up-regulated in the normoxic co-culture and the hypoxic co-
culture. 
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NSC	  gene	  expression-­‐	  HPX	  co-­‐culture	  (HPX)	  
Gene	   Function	  (Cytokines/Chemokines)	   Fold	  Regulation	  
CCL5	   Chemokine	   3	  
CCL12	   Chemokine	   2.7	  
Csf1	   Chemokine	   2.4	  CCR5	   Chemokine	  receptor	   12.5	  
CXCL1	   Chemokine	   11	  
CXCL10	   Chemokine	   11.3	  
Icam1	   Adhesion	  molecule	   8.9	  
Vcam1	   Adhesion	  molecule	   2.8	  
	  We	  also	  examined	  genes	  involved	  in	  immune	  cell	  activation	  and	  found	  up-­‐regulation	  of	  many	  genes	  involved	  in	  the	  adaptive	  immune	  response	  (Figure	  7).	  The	  cytokine	  IL6	  was	  up-­‐regulated	  in	  the	  normoxic	  co-­‐culture	  (4.7	  fold)	  and	  the	  hypoxic	  co-­‐culture	  (7.8	  fold),	  whereas	  interferon-­‐γ	  (IFNG)	  was	  highly	  up-­‐regulated	  in	  the	  hypoxic	  co-­‐culture	  (20	  fold)	  but	  down-­‐regulated	  in	  the	  normoxic	  co-­‐culture	  (-­‐3.4	  fold)	  (Tables	  8-­‐9).	  Furthermore,	  genes	  involved	  in	  T-­‐cell	  activation	  and	  co-­‐stimulation,	  including	  CD40	  and	  CD80,	  were	  also	  up-­‐regulated	  in	  the	  co-­‐culture	  but	  not	  the	  controls.	  This	  suggests	  an	  important	  and	  novel	  mechanism	  for	  activating	  adaptive	  immune	  processes	  and	  anti-­‐tumor	  responses.	  	  
Table 7: Gene expression analysis of RT-PCR data from NSCs co-cultured with GL261s 
under hypoxic conditions. Changes are relative to hypoxic control group. 
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NSC	  gene	  expression-­‐	  NMX	  co-­‐culture	  (NMX)	  
Gene	  Symbol	   Function	  (Immune-­‐related)	   Fold	  Regulation	  
CD40	   Adaptive	  immunity-­‐	  costimulatory	  signal	   3	  
CD80	   Adaptive	  immunity-­‐	  costimulatory	  signal	   2.2	  
Icam1	   T-­‐cell	  receptor	  accessory	  ligand	   7.1	  
IL6	   Cytokine	   4.7	  IFNG	   Cytokine	   -­‐3.4	  
	  
NSC	  gene	  expression-­‐	  HPX	  co-­‐culture	  (HPX)	  
Gene	  Symbol	   Function	  (Immune-­‐related)	   Fold	  Regulation	  
CD40	   Adaptive	  immunity-­‐	  costimulatory	  signal	   5	  
CD80	   Adaptive	  immunity-­‐	  costimulatory	  signal	   3.2	  
Icam1	   T-­‐cell	  receptor	  accessory	  ligand	   8.9	  IFNG	   Cytokine	   20	  
IL6	   Cytokine	   7.8	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Figure 7: Gene	  expression	  changes	  represented	  by	  fold	  change	  relative	  to	  corresponding	  control.	  The	  NMX	  co-­‐culture	  changes	  are	  relative	  to	  the	  normoxic	  control	  and	  HPX	  co-­‐cultures	  changes	  are	  relative	  to	  the	  hypoxic	  control. 
 
Table 8: Gene expression analysis of RT-PCR data from NSCs co-cultured with GL261s under 
normoxic conditions. Changes are relative to normoxic control group. 
Table 9: Gene expression analysis of RT-PCR data from NSCs co-cultured with GL261s under 
hypoxic conditions. Changes are relative to hypoxic control group. 
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Taking	  together	  the	  expression	  data	  from	  the	  tumor	  necrosis	  family	  ligands	  along	  with	  the	  cytokine/chemokine	  and	  immune	  signaling	  molecules,	  it	  can	  be	  concluded	  that	  NSCs	  respond	  to	  GL261	  interactions	  by	  up-­‐regulating	  ligands	  involved	  in	  inducing	  apoptosis	  and	  also	  by	  up-­‐regulating	  many	  immune-­‐related	  genes	  that	  are	  involved	  in	  immune	  cell	  recruitment	  and	  activation.	  	   DISCUSSION	  	  	  	  Although	  the	  migratory	  nature	  of	  NSCs	  towards	  glioblastoma	  tumors	  has	  been	  well	  characterized,	  the	  actions	  of	  NSCs	  within	  the	  tumor	  microenvironment	  and	  the	  intercellular	  relationship	  between	  NSCs	  and	  gliomas	  in	  regard	  to	  tumor	  progression	  is	  not	  well	  studied.	  Glass	  et	  al.	  (2005)	  found	  that	  NSCs	  can	  prolong	  survival	  in	  animal	  models	  of	  GBM	  and	  further	  investigation	  found	  that	  NSCs	  could	  directly	  suppress	  and	  induce	  apoptosis	  in	  GBM	  co-­‐cultures.	  However,	  the	  mechanism	  behind	  this	  suppressive	  effect	  has	  not	  been	  studied.	  This	  is	  the	  first	  study	  to	  examine	  the	  intercellular	  interactions	  between	  NSCs	  and	  GBM	  cells	  at	  the	  genetic	  level	  and	  the	  subsequent	  influence	  on	  gene	  expression.	  The	  objectives	  here	  were	  to	  study	  the	  mode	  and	  mechanism	  behind	  NSC-­‐mediated	  tumor	  suppression.	  We	  performed	  co-­‐culture	  proliferation	  assays	  in	  combination	  with	  gene	  expression	  analysis	  to	  show	  that	  there	  is	  a	  two-­‐way	  communication	  between	  the	  NSCs	  and	  the	  GL261s	  that	  results	  in	  decreased	  GL261	  proliferation	  and	  changes	  to	  survival	  and	  apoptotic-­‐related	  gene	  expression.	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MODE	  AND	  MECHANISM	  To	  study	  the	  mode	  of	  intercellular	  communication	  we	  utilized	  in	  vitro	  culturing	  inserts	  that	  separate	  the	  two	  cell	  types	  but	  allow	  for	  the	  exchange	  of	  factors	  through	  the	  semi-­‐permeable	  membrane.	  This	  co-­‐culture	  system	  was	  advantageous	  in	  that	  it	  allowed	  for	  us	  to	  examine	  the	  specific	  interactions	  between	  the	  NSCs	  and	  GBMs	  while	  excluding	  many	  other	  cell	  types	  of	  the	  heterogeneous	  tumor	  microenvironment.	  Our	  findings	  suggest	  that	  these	  interactions	  are	  contact	  independent	  and	  are	  transmitted	  through	  soluble	  factors	  or	  microvesicles.	  The	  gene	  expression	  data	  has	  provided	  information	  on	  the	  suspected	  factors	  involved	  in	  this	  communication.	  An	  important	  finding	  was	  the	  increased	  expression	  of	  TNFα	  and	  Fas-­‐ligand	  by	  the	  NSCs.	  This	  correlated	  with	  the	  decreased	  GL261	  proliferation	  and/or	  viability	  and	  the	  up-­‐regulation	  of	  stressed-­‐activated	  MAP2k6	  and	  the	  down-­‐regulation	  of	  anti-­‐apoptotic	  BCL2	  in	  the	  GL261s	  from	  the	  co-­‐cultures	  but	  not	  the	  controls.	  	   GL261	  SUPPRESSION	  BY	  NEURAL	  STEM	  CELLS	  TNFα	  and	  Fas-­‐ligand	  are	  proteins	  of	  the	  tumor	  necrosis	  factor	  super	  family	  that	  are	  involved	  in	  the	  pro-­‐inflammatory	  immune	  response	  and	  also	  programmed	  cell	  death.	  TNFα	  has	  a	  cytotoxic	  effect	  on	  many	  tumor	  cell	  lines	  and	  can	  cause	  tumor	  necrosis	  in	  many	  animal	  models	  (Old,	  1988).	  The	  production	  of	  tumor	  necrosis	  factor	  (TNF)	  ligands	  by	  NSCs	  has	  been	  demonstrated	  in	  other	  circumstances	  but	  never	  before	  in	  the	  context	  of	  tumor	  suppression.	  Klassen	  et	  al.	  found	  that	  NSCs	  constitutively	  produce	  TNFα	  under	  normal	  culturing	  conditions	  and	  Covacu	  et	  al.	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found	  that	  this	  production	  is	  mediated	  through	  toll-­‐like	  receptor	  (TLR)	  activation	  (Klassen	  et	  al.,	  2003)	  (Covacu	  et	  al.,	  2009).	  Therefore,	  this	  finding	  suggests	  a	  possible	  mechanism	  for	  NSC-­‐mediated	  tumor	  suppression	  whereby	  NSC	  signaling	  through	  TLRs	  leads	  to	  TNFα	  production	  and	  GBM	  cell	  death.	  	  TNFα	  is	  produced	  as	  a	  transmembrane	  protein	  arranged	  into	  homotrimers	  that	  get	  released	  as	  a	  soluble	  cytokine	  through	  the	  proteolytic	  cleavage	  by	  the	  TNF	  alpha-­‐converting	  enzyme	  (TACE)	  (Wajant	  et	  al.,	  2003).	  This	  ligand	  can	  then	  interact	  with	  the	  TNF-­‐receptors	  that	  are	  expressed	  on	  most	  cell	  types	  including	  glioblastoma	  (Tada	  et	  al.,	  1994).	  TNF	  has	  a	  diverse	  range	  of	  biological	  functions,	  including	  involvement	  in	  development	  and	  regeneration	  but	  also	  tissue	  destruction.	  The	  differential	  outcome	  has	  been	  attributed	  to	  cell	  type,	  physiological	  context,	  receptor	  subtype,	  timing	  and	  duration	  (Wajant	  et	  al.,	  2003).	  	  Activation	  of	  the	  TNF-­‐receptor	  (TNF-­‐R1)	  signals	  to	  the	  intracellular	  death	  domain	  (DD)	  and	  initiates	  the	  coupling	  of	  the	  death	  receptor	  to	  caspase	  activation	  and	  apoptosis	  (Tartaglia	  et	  al.,	  1993).	  Downstream	  signaling	  can	  lead	  to	  the	  activation	  of	  NF-­‐κB	  and	  stress-­‐induced	  MAPK	  pathways	  through	  the	  TRAF2	  (TNF	  receptor-­‐associated	  factor-­‐2)	  adaptor	  protein	  or	  it	  can	  lead	  to	  caspase	  activation	  through	  the	  Fas-­‐associated	  death	  domain	  protein	  (FADD)	  (described	  below).	  Signaling	  through	  TRAF2	  activates	  the	  MAP3K	  apoptosis	  signal-­‐regulated	  kinase-­‐1	  (ASK1),	  leading	  to	  the	  downstream	  activation	  of	  stress-­‐induced	  p38-­‐MAPK	  and	  the	  c-­‐Jun	  N-­‐terminal	  kinase	  (JNK).	  These	  kinase	  pathways	  are	  simultaneously	  activated	  in	  response	  to	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cellular	  and	  environmental	  stresses	  and	  can	  respond	  by	  modulating	  the	  cell	  cycle	  and	  initiating	  programmed	  cell	  death.	  p38-­‐MAPK	  is	  directly	  activated	  by	  MKK6	  (MAP2K6).	  JNK	  is	  directly	  activated	  by	  MKK4/7	  and	  induces	  programmed	  cell	  death	  mainly	  through	  the	  activation	  of	  the	  AP-­‐1	  transcription	  factor	  component	  c-­‐Jun	  and	  also	  by	  the	  phosphorylation	  and	  inhibition	  of	  anti-­‐apoptotic	  protein	  BCL2	  (Wada	  and	  Penninger,	  2004;	  Wajant	  et	  al.,	  2003).	  	  We	  found	  MAP2K6	  to	  be	  up-­‐regulated	  in	  the	  GL261	  cells	  following	  NSC	  co-­‐culture	  and	  this	  corresponded	  with	  the	  increased	  TNFα	  expression	  by	  the	  NSCs.	  In	  another	  study,	  fibroblasts	  treated	  with	  TNFα	  were	  shown	  to	  induce	  apoptosis	  through	  ASK1-­‐mediated	  MAP2K6	  and	  JNK	  activation	  (Ichijo	  et	  al.,	  1997).	  This	  could	  be	  the	  case	  in	  our	  experiment,	  however	  the	  kinase	  activation	  status	  needs	  to	  be	  determined	  along	  with	  downstream	  p38	  signaling	  targets	  to	  confirm	  a	  connection	  with	  decreased	  cell	  viability.	  Furthermore,	  the	  results	  from	  the	  alamarblue	  assays	  on	  GL261s	  were	  initially	  interpreted	  as	  a	  decrease	  in	  cell	  proliferation	  due	  to	  the	  decreased	  alamarblue	  reduction.	  However,	  the	  reduced	  reduction	  rate	  could	  also	  reflect	  a	  decrease	  in	  cell	  number	  caused	  by	  cell	  death.	  These	  findings	  would	  support	  the	  results	  from	  the	  Glass	  et	  al.	  study	  where	  they	  showed	  NSC-­‐induced	  glioma	  apoptosis.	  Viability	  assays	  will	  need	  to	  be	  performed	  to	  confirm	  this	  outcome.	  	  Fas-­‐ligand	  was	  also	  found	  up-­‐regulated	  by	  NSCs	  in	  the	  co-­‐culture	  relative	  to	  controls.	  The	  Fas/Fas-­‐ligand	  system	  is	  the	  prototypic	  mechanism	  for	  extrinsic	  cell	  death	  that	  is	  involved	  in	  cell-­‐mediated	  cytotoxicity,	  immune	  regulation,	  and	  also	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counterattack	  by	  many	  cancer	  cells	  (Choi	  and	  Benveniste,	  2004).	  This	  suggests	  another	  NSC-­‐mediated	  mechanism	  to	  decrease	  GL261	  viability	  through	  programmed	  cell	  death.	  Fas-­‐ligand	  (Tnfsf6)	  is	  a	  40-­‐kDa	  protein	  and	  another	  member	  of	  the	  tumor	  necrosis	  factor	  super	  family.	  Fas-­‐ligand	  binds	  to	  its	  transmembrane	  glycoprotein	  counterpart	  Fas/APO-­‐1	  on	  target	  cells	  to	  initiate	  apoptosis	  through	  caspase	  activation.	  Similarly	  to	  TNFα,	  Fas-­‐ligand	  can	  function	  as	  a	  transmembrane	  ligand	  or	  as	  a	  soluble	  form	  following	  cleavage	  by	  several	  matrix	  metalloproteinases.	  Activated	  T	  cells	  and	  NK	  cells	  are	  the	  major	  cells	  that	  express	  Fas-­‐ligand	  as	  part	  of	  their	  cytotoxic	  machinery,	  however	  neurons,	  astrocytes,	  and	  neural	  stem	  cells	  have	  been	  shown	  to	  express	  Fas-­‐ligand	  for	  participation	  in	  immune	  regulation	  in	  the	  CNS	  (Choi	  and	  Benveniste,	  2004)	  (Carpentier	  and	  Palmer,	  2009).	  GBM	  cells	  have	  also	  been	  shown	  to	  express	  Fas-­‐ligand	  and	  the	  in	  vivo	  expression	  has	  been	  positively	  correlated	  with	  the	  malignancy	  grade	  in	  CNS	  tumors.	  This	  is	  associated	  with	  their	  ability	  to	  kill	  infiltrating	  lymphocytes	  (Saas	  et	  al.,	  1997).	  Glioblastomas	  also	  express	  relatively	  high	  levels	  of	  Fas/APO-­‐1	  and	  are	  sensitive	  to	  Fas-­‐mediated	  apoptosis	  in	  vitro,	  although	  their	  sensitivity	  is	  variable.	  	  	  Signaling	  by	  these	  tumor	  necrosis	  factor	  family	  death	  receptors	  leads	  to	  caspase	  activation	  and	  cellular	  apoptosis.	  Common	  to	  most	  death	  receptors	  is	  the	  FADD	  adaptor	  protein,	  which	  associates	  with	  the	  intracellular	  domain	  of	  TNF-­‐R1	  through	  TRADD	  (TNF	  receptor-­‐associated	  death	  domain	  protein)	  and	  also	  with	  DISC	  (death-­‐inducing	  signaling	  complex)	  following	  Fas/APO-­‐1	  activation	  to	  mediate	  the	  recruitment	  and	  activation	  of	  initiator	  procaspase-­‐8	  and	  10,	  which	  then	  continue	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downstream	  to	  activate	  executioner	  procaspases	  for	  initiation	  of	  apoptosis	  (Wajant	  et	  al.,	  2003).	  Fas	  activation	  can	  also	  transduce	  stress	  signals	  through	  adaptor	  protein	  Daxx	  to	  activate	  ASK1	  and	  the	  downstream	  JNK	  pathway	  to	  induce	  apoptosis	  (Choi	  and	  Benveniste,	  2004).	  	  	  In	  addition	  to	  extrinsic	  death	  receptor	  ligands	  in	  the	  co-­‐culture	  experiment,	  we	  also	  found	  changes	  in	  the	  intrinsic	  pathways	  that	  regulate	  apoptosis	  in	  response	  to	  stressful	  stimuli.	  Intrinsic	  apoptotic	  pathways	  involve	  triggering	  the	  release	  of	  mitochondrial	  protein	  cytochrome	  C	  from	  the	  outer	  membrane.	  It	  then	  enters	  the	  cytosol	  and	  binds	  to	  a	  procaspase-­‐activating	  adaptor	  protein	  called	  the	  apoptotic	  protease	  activating	  factor-­‐1	  (Apaf1).	  Apaf1	  oligomerizes	  into	  an	  apoptosome	  heptamer	  that	  recruits	  and	  activates	  initiator	  procaspase	  protein	  9	  to	  facilitate	  the	  downstream	  activation	  of	  executioner	  caspases.	  This	  intrinsic	  apoptotic	  pathway	  is	  regulated	  by	  a	  class	  of	  BCL2	  proteins	  with	  both	  pro-­‐apoptotic	  and	  anti-­‐apoptotic	  effects	  by	  controlling	  the	  release	  of	  cytochrome	  C	  and	  other	  intermembrane	  mitochondrial	  components	  (Alberts	  et	  al.,	  2008).	  The	  pro-­‐apoptotic	  BH123	  proteins	  include	  mitochondrial-­‐bound	  Bak	  and	  cytosolic	  Bax.	  Following	  intrinsic	  apoptotic	  stimuli	  these	  proteins	  form	  oligomers	  in	  the	  mitochondrial	  outer	  member	  to	  promote	  the	  release	  of	  cytochrome	  C.	  The	  anti-­‐apoptotic	  BCL2	  proteins	  include	  BCL2	  itself	  and	  BCL-­‐XL.	  These	  proteins	  act	  to	  stability	  the	  mitochondrial	  membrane	  by	  binding	  and	  inhibiting	  Bax	  and	  Bak	  from	  oligomerizing	  (Alberts	  et	  al.,	  2008).	  Nakasu	  et	  al.	  found	  that	  many	  CNS	  malignancies	  including	  low	  and	  high-­‐grade	  astrocytomas	  express	  a	  relatively	  high	  level	  of	  BCL2	  compared	  to	  their	  non-­‐
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malignant	  astrocytic	  counterparts	  (Nakasu	  et	  al.,	  1994).	  However,	  as	  stated	  before,	  TNF-­‐induced	  JNK	  activation	  has	  the	  ability	  to	  inhibit	  BCL2	  by	  phosphorylation	  to	  suppress	  its	  inhibitory	  effect.	  Interestingly,	  our	  findings	  show	  that	  BCL2	  expression	  is	  significantly	  down-­‐regulated	  in	  GL261s	  co-­‐cultured	  with	  NSCs	  under	  normoxic	  conditions.	  This	  corresponds	  with	  the	  decreased	  GL261	  proliferation	  and/or	  viability	  and	  the	  increase	  in	  death-­‐related	  ligands	  by	  the	  NSCs,	  although	  the	  connection	  between	  TNF	  signaling	  and	  BCL2	  transcriptional	  regulation	  has	  not	  been	  determined.	  	  Taken	  together,	  we	  found	  that	  NSCs	  were	  capable	  of	  suppressing	  GL261	  proliferation	  and/or	  viability	  through	  releasable	  factors	  that	  are	  suspected	  to	  be	  TNFα	  and	  Fas-­‐ligand	  based	  on	  gene	  expression	  data.	  These	  factors	  could	  be	  regulated	  through	  toll-­‐like	  receptor	  activation	  and	  NF-­‐κB-­‐regulated	  cytokine	  production.	  These	  tumor	  necrosis	  factor	  proteins	  are	  suspected	  to	  suppress	  GL261	  cell	  cycle	  regulation	  and	  programmed	  cell	  death	  through	  Fas/APO-­‐1	  and	  TNF-­‐receptors.	  Follow	  up	  experiments	  will	  confirm	  the	  TLR2/4	  activation	  on	  NSCs	  following	  GL261	  co-­‐culture	  along	  with	  a	  western	  blot	  using	  the	  conditioned	  media	  from	  the	  co-­‐culture	  to	  confirm	  the	  presence	  and	  up-­‐regulation	  of	  TNFα	  and	  Fas-­‐ligand	  proteins.	  	   	  	  	  
	  	   47	  
HYPOXIA	  PROMOTES	  GL261	  SURVIVAL	  Interestingly,	  the	  NSC-­‐mediated	  GL261	  suppression	  only	  occurred	  under	  normoxic	  conditions.	  No	  changes	  in	  proliferation	  were	  observed	  in	  the	  hypoxic	  co-­‐culture	  and	  this	  corresponded	  with	  a	  different	  gene	  expression	  profile.	  This	  could	  be	  due	  to	  the	  decreased	  expression	  of	  TNFα	  by	  NSCs	  in	  the	  hypoxic	  co-­‐culture,	  despite	  similar	  levels	  of	  Fas-­‐ligand.	  These	  contrasting	  results	  also	  could	  be	  due	  to	  survival	  mechanisms	  initiated	  by	  the	  hypoxic	  culturing	  conditions.	  Hypoxia	  is	  an	  important	  aspect	  of	  cancer	  biology	  and	  has	  been	  associated	  with	  tumor	  progression,	  metastasis,	  and	  resistance	  to	  therapy.	  It	  has	  also	  been	  associated	  with	  poor	  survival	  in	  patients	  with	  CNS	  malignancies	  as	  well	  as	  other	  cancer	  types	  (Harris,	  2002)	  (Hockel	  and	  Vaupel,	  2001).	  Cancer	  cells	  show	  increased	  levels	  of	  HIF-­‐1a	  in	  the	  cytoplasm	  and	  nucleus	  of	  many	  tumors	  and	  the	  overexpression	  of	  HIF-­‐1a	  was	  associated	  with	  increased	  cell	  proliferation	  (Talks	  et	  al.,	  2000)	  (Zhong	  et	  al.,	  1999).	  Many	  hypoxia-­‐inducible	  genes	  regulate	  processes	  such	  as	  cell	  proliferation,	  metabolism,	  and	  migration	  (Rankin	  and	  Giaccia,	  2008).	  Hypoxia	  has	  also	  been	  shown	  to	  promote	  survival	  through	  NF-­‐κB	  target	  genes.	  Hypoxia	  causes	  the	  activation	  of	  NF-­‐κB	  through	  phosphorylation	  and	  degradation	  of	  I-­‐κB,	  leading	  to	  increased	  NF-­‐κB	  DNA	  binding	  and	  transcriptional	  activity	  (Koong	  et	  al.,	  1994).	  	  Importantly,	  NF-­‐κB	  is	  also	  activated	  downstream	  of	  TNF-­‐R	  and	  Fas/APO-­‐1	  signaling	  and	  has	  a	  role	  in	  regulating	  the	  TNF-­‐induced	  programmed	  cell	  death	  (Wajant	  et	  al.,	  2003).	  In	  addition	  to	  the	  TNF-­‐signal	  transduction	  through	  the	  TNF-­‐R1/FADD	  intracellular	  death	  domain	  that	  leads	  to	  apoptosis	  through	  caspase	  activation,	  TNF-­‐
	  	   48	  
R1	  signaling	  can	  also	  lead	  to	  NF-­‐κB	  activation	  through	  TRAF2.	  TRAF2	  is	  involved	  in	  recruiting	  IKK	  into	  the	  TNF-­‐R1	  signaling	  complex	  and	  along	  with	  RIP	  (receptor-­‐interacting	  kinase)	  mediates	  its	  activation	  by	  interacting	  with	  the	  NEMO	  domain,	  resulting	  in	  I-­‐κB	  degradation	  and	  NF-­‐κB	  activation.	  	  	  Fibroblasts	  with	  a	  RelA	  deletion	  have	  an	  inability	  to	  transcriptionally	  activate	  TNF	  target	  genes.	  However,	  this	  compromised	  TNF-­‐mediated	  NF-­‐κB	  activation	  shows	  increased	  sensitivity	  towards	  TNF-­‐R	  apoptosis.	  This	  suggested	  that	  NF-­‐κB	  could	  regulate	  protective	  mechanisms	  against	  the	  cytotoxic	  effect	  of	  TNFα.	  It	  was	  also	  shown	  that	  the	  anti-­‐apoptotic	  protein	  A20	  was	  normally	  induced	  in	  wildtype	  expressing	  RelA	  cells	  but	  not	  RelA-­‐negative	  cells	  following	  TNFα	  treatment	  (Beg	  and	  Baltimore,	  1996).	  	  RelA-­‐negative	  fibroblasts	  were	  also	  used	  to	  investigate	  the	  effect	  of	  NF-­‐κB	  activation	  on	  TNF-­‐induced	  caspase	  and	  JNK	  activity.	  NF-­‐κB	  target	  gene	  Gadd45b,	  a	  member	  of	  the	  of	  the	  Gadd45	  family	  of	  inducible	  factors	  associated	  with	  cell-­‐cycle	  control	  and	  DNA	  repair,	  was	  found	  to	  be	  strongly	  induced	  by	  TNFα	  in	  wildtype	  fibroblasts	  but	  not	  RelA-­‐negative	  cells.	  Expressing	  Gadd45b	  into	  the	  mutant	  cells	  restored	  viability	  following	  TNF	  treatment	  and	  suppressed	  caspase	  activity	  in	  NF-­‐κB	  deficient	  cells.	  They	  also	  showed	  that	  JNK	  activity	  was	  suppressed	  by	  Gadd45b.	  Normally,	  JNK	  activity	  is	  only	  transiently	  increased	  following	  TNF	  treatment	  in	  wildtype	  cells,	  but	  it	  is	  prolonged	  in	  NF-­‐κB	  deficient	  cells.	  The	  overexpression	  of	  Gadd45	  impaired	  and	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suppressed	  this	  prolonged	  activity,	  confirming	  that	  Gadd45b	  mediated	  the	  inhibitory	  effect	  of	  NF-­‐κB	  on	  JNK	  activity	  (De	  Smaele	  et	  al.,	  2001).	  	  From	  our	  gene	  expression	  analysis	  we	  found	  increased	  levels	  of	  Gadd45b	  in	  the	  Gl261	  cells	  under	  hypoxic	  co-­‐culture	  conditions.	  The	  increase	  in	  this	  anti-­‐apoptotic	  gene	  could	  have	  provided	  protection	  and	  counteracted	  the	  apoptotic	  signal	  from	  Fas-­‐ligand	  produced	  from	  the	  NSCs.	  It	  is	  proposed	  here	  that	  the	  death	  receptor	  activation	  and	  signaling	  is	  shifted	  in	  GL261	  cells	  under	  the	  different	  culturing	  conditions.	  Under	  normoxic	  conditions,	  TNF-­‐R	  and	  Fas/APO-­‐1	  activation	  favors	  the	  FADD	  signaling	  route	  to	  caspase	  activation	  and	  apoptosis.	  However,	  under	  hypoxic	  conditions,	  HIF-­‐1	  and	  NF-­‐κB	  activity	  promote	  survival	  mechanisms	  through	  anti-­‐apoptotic	  target	  genes.	  The	  mechanisms	  of	  NF-­‐κB	  in	  cell	  survival	  and	  oncogenesis	  have	  been	  well	  documented	  (Baldwin,	  2001).	  These	  in	  vitro	  experiments	  have	  demonstrated	  the	  cell-­‐autonomous	  effects	  of	  glioma	  cells	  in	  responding	  to	  stressful	  conditions	  to	  resist	  programmed	  cell	  death	  and	  to	  promote	  tumor	  progression.	  	   NEURAL	  STEM	  CELL	  IMMUNE	  SIGNALING	  AND	  ACTIVATION	  Our	  survival/apoptosis	  data	  has	  shown	  a	  direct	  mode	  of	  intercellular	  communication	  between	  NSCs	  and	  GL261	  glioma	  cells	  based	  on	  the	  in	  vitro	  co-­‐culturing	  system.	  The	  advantages	  of	  this	  system	  were	  mentioned	  above	  but	  there	  are	  also	  disadvantages	  of	  this	  culturing	  system	  such	  as	  exclusion	  of	  the	  immune	  system	  and	  the	  known	  role	  of	  stem	  cells	  in	  immune	  signaling.	  However,	  gene	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expression	  analysis	  has	  provided	  some	  insight	  into	  the	  cytokine	  profiles	  produced	  by	  NSCs	  and	  another	  potential	  mechanism	  for	  tumor	  suppression.	  	  Similar	  to	  the	  immune	  signaling	  involved	  during	  the	  wound	  repair	  process,	  we	  found	  that	  many	  cytokines	  and	  chemokines	  associated	  with	  immune	  cell	  recruitment	  and	  activation	  were	  up-­‐regulated	  by	  NSCs	  in	  the	  co-­‐culture	  experiment.	  These	  changes	  were	  primarily	  influenced	  by	  the	  interactions	  with	  GL261s	  rather	  than	  the	  oxygen	  levels	  since	  the	  expression	  profiles	  were	  similar	  between	  the	  normoxic	  and	  hypoxic	  co-­‐culturing	  conditions.	  These	  chemokines	  are	  known	  to	  recruit	  both	  innate	  and	  adaptive	  immune	  cells.	  CXCL1	  and	  CXCL3	  are	  ligands	  for	  receptor	  CXCR2	  that	  is	  expressed	  primarily	  by	  monocytes	  and	  neutrophils,	  whereas	  CXCL9	  and	  CXCL10	  are	  ligands	  for	  receptor	  CXCR3	  that	  is	  expressed	  primarily	  by	  T-­‐cells.	  Chemokines	  such	  as	  CCL5	  (ligand	  for	  CCR3)	  and	  CCL2	  (ligand	  for	  CCR2)	  target	  a	  more	  broad	  range	  of	  immune	  cells,	  including	  macrophages,	  dendritic	  cells,	  and	  T-­‐cells.	  Additional	  immune-­‐related	  genes	  up-­‐regulated	  by	  NSCs	  include	  IL-­‐6,	  IFNG,	  and	  also	  co-­‐stimulatory	  molecules	  involved	  in	  T-­‐cell	  activation.	  IL-­‐6	  is	  an	  important	  pro-­‐inflammatory	  cytokine	  involved	  in	  the	  innate	  immune	  response.	  It	  was	  found	  highly	  expressed	  by	  NSCs	  in	  both	  co-­‐cultures.	  IFNG	  is	  more	  involved	  in	  the	  adaptive	  immune	  response	  by	  activating	  T-­‐cells	  and	  increasing	  antigen	  processing	  and	  MHC1	  expression.	  It	  was	  found	  highly	  expressed	  in	  the	  hypoxic	  co-­‐culture.	  	  Interestingly,	  hematopoietic	  stem	  cells	  (HSCs)	  were	  found	  to	  serve	  a	  similar	  role	  in	  pathogen	  detection	  and	  immune	  signaling.	  Zhao	  et	  al.	  found	  that	  HSCs	  are	  actively	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engaged	  in	  converting	  danger	  signals	  such	  as	  lipopolysaccharide	  (LPS)	  into	  cytokine	  signals	  to	  regulate	  stress-­‐induced	  hematopoiesis.	  This	  detection	  was	  mediated	  through	  TLR	  signaling	  and	  NF-­‐κB	  activation,	  resulting	  primarily	  in	  IL-­‐6	  cytokine	  production	  (Zhao	  et	  al.,	  2014).	  	  Our	  data	  also	  suggest	  a	  role	  of	  NSCs	  in	  adaptive	  immune	  support	  through	  the	  up-­‐regulation	  of	  co-­‐stimulatory	  molecules	  CD40	  and	  CD80.	  	  These	  molecules	  are	  primarily	  expressed	  by	  antigen-­‐presenting	  cells	  and	  used	  to	  provide	  a	  second	  co-­‐stimulatory	  signal	  for	  T-­‐cell	  activation.	  These	  findings	  are	  preliminary	  and	  need	  to	  be	  confirmed.	  However,	  there	  is	  some	  evidence	  that	  NSCs	  can	  express	  co-­‐stimulatory	  molecules	  in	  response	  to	  inflammatory	  stimuli.	  In	  mouse	  models	  of	  multiple	  sclerosis,	  increased	  expression	  of	  CD80	  was	  observed	  in	  the	  subventricular	  zone	  and	  further	  analysis	  showed	  that	  CD80	  and	  CD86	  were	  up-­‐regulated	  by	  NSCs	  in	  response	  to	  inflammatory	  cytokines	  TNF	  and	  IFNG.	  It	  was	  also	  found	  that	  these	  NSCs	  could	  interact	  with	  and	  co-­‐stimulate	  allogenic	  T-­‐cells	  in	  vitro	  (Imitola	  et	  al.,	  2004).	  Taken	  together,	  we	  propose	  that	  another	  important	  mode	  in	  NSC-­‐mediated	  tumor	  suppression	  could	  involve	  an	  indirect	  role	  in	  mediating	  an	  anti-­‐tumor	  immune	  response.	  NSCs	  have	  been	  shown	  to	  participate	  in	  immune	  signaling	  during	  wound	  repair	  and	  our	  evidence	  here	  suggests	  a	  similar	  mechanism.	  	  In	  summary,	  we	  have	  demonstrated	  two	  potential	  mechanisms	  for	  NSC-­‐mediated	  tumor	  suppression	  (Figure	  8).	  The	  first	  mechanism	  involves	  interaction	  between	  NSCs	  and	  GL261s	  that	  we	  showed	  using	  a	  co-­‐culture	  system.	  This	  resulted	  in	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reduced	  GL261	  viability	  that	  was	  independent	  of	  cell-­‐cell	  contact,	  suggesting	  that	  this	  mechanism	  was	  mediated	  by	  factors	  released	  from	  NSCs.	  This	  reduced	  viability	  correlated	  with	  the	  up-­‐regulation	  of	  TNF-­‐α	  and	  Fas-­‐ligand	  by	  NSCs.	  TNF-­‐α	  and	  Fas-­‐ligand	  have	  cytotoxic	  effects	  on	  many	  different	  tumor	  cell	  lines	  in	  vitro	  and	  necrotic	  effects	  when	  administered	  in	  vivo	  (Old,	  1988).	  Therefore,	  we	  suspect	  that	  the	  production	  of	  these	  cell	  death	  ligands	  could	  be	  a	  mechanism	  for	  NSC-­‐mediated	  tumor	  suppression.	  However,	  this	  effect	  was	  not	  observed	  when	  co-­‐cultured	  under	  hypoxic	  conditions,	  where	  we	  found	  changes	  to	  GL261	  gene	  expression	  and	  the	  up-­‐regulation	  of	  many	  survival	  genes,	  including	  Adrenomedullin,	  Bcl2,	  and	  Gadd45b.	  This	  is	  consistent	  with	  many	  studies	  reporting	  on	  the	  importance	  of	  hypoxia	  in	  cancer	  progression	  (Harris,	  2002).	  	  We	  also	  propose	  a	  second	  mechanism	  of	  NSC-­‐mediated	  tumor	  suppression	  based	  on	  our	  findings	  from	  the	  NSC	  gene	  expression	  array.	  We	  found	  many	  immune-­‐related	  genes	  up-­‐regulated	  in	  NSCs	  following	  GL261	  co-­‐culture,	  including	  several	  pro-­‐inflammatory	  cytokines	  and	  chemokines	  that	  are	  important	  for	  recruiting	  and	  activating	  immune	  cells.	  Therefore,	  we	  propose	  an	  indirect	  mechanism	  involving	  immune	  signaling	  that	  could	  potentially	  lead	  to	  an	  anti-­‐tumor	  immune	  response.	  Further	  studies	  into	  the	  communication	  between	  NSCs,	  immune	  cells,	  and	  glioma	  cells	  are	  needed	  in	  order	  to	  better	  understand	  the	  involvement	  of	  NSCs	  in	  mediating	  this	  immune	  response	  and	  the	  potential	  effectiveness	  of	  promoting	  a	  stronger	  endogenous	  NSC	  population	  and	  the	  beneficial	  use	  of	  exogenous	  NSCs	  modified	  to	  better	  facilitate	  the	  immune	  response.	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  CXCL1,	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Figure	  8:	  Model	  of	  intercellular	  interactions	  between	  the	  tumor	  cells,	  NSCs,	  and	  immune	  cells.	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APPENDIX	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Supplemental	  figure	  1:	  Preliminary	  alamarblue	  testing	  to	  compare	  GL261	  proliferation	  rates	  with	  normal	  DMEM/10%	  FBS	  media	  and	  neurocult/EGF	  media	  (SCM)	  under	  normoxic	  and	  hypoxic	  conditions	  	  
Supplemental	  figure	  2:	  Preliminary	  alamarblue	  testing	  to	  determine	  the	  proper	  alamarblue	  incubation	  duration.	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Position	   Symbol	   Description	  A01	   Adm	   Adrenomedullin	  A02	   Agt	   Angiotensinogen	  (serpin	  peptidase	  inhibitor,	  clade	  A,	  member	  8)	  A03	   Akt1	   Thymoma	  viral	  proto-­‐oncogene	  1	  A04	   Aldh3a2	   Aldehyde	  dehydrogenase	  family	  3,	  subfamily	  A2	  A05	   Bcl2a1a	   B-­‐cell	  leukemia/lymphoma	  2	  related	  protein	  A1a	  A06	   Bcl2l1	   Bcl2-­‐like	  1	  A07	   Birc2	   Baculoviral	  IAP	  repeat-­‐containing	  2	  A08	   Birc3	   Baculoviral	  IAP	  repeat-­‐containing	  3	  A09	   C3	   Complement	  component	  3	  A10	   C4a	   Complement	  component	  4A	  (Rodgers	  blood	  group)	  A11	   Ccl12	   Chemokine	  (C-­‐C	  motif)	  ligand	  12	  A12	   Ccl22	   Chemokine	  (C-­‐C	  motif)	  ligand	  22	  B01	   Ccl5	   Chemokine	  (C-­‐C	  motif)	  ligand	  5	  B02	   Ccnd1	   Cyclin	  D1	  B03	   Ccr5	   Chemokine	  (C-­‐C	  motif)	  receptor	  5	  B04	   Cd40	   CD40	  antigen	  B05	   Cd74	   CD74	  antigen	  B06	   Cd80	   CD80	  antigen	  B07	   Cd83	   CD83	  antigen	  B08	   Cdkn1a	   Cyclin-­‐dependent	  kinase	  inhibitor	  1A	  (P21)	  B09	   Cfb	   Complement	  factor	  B	  B10	   Csf1	   Colony	  stimulating	  factor	  1	  (macrophage)	  B11	   Csf2	   Colony	  stimulating	  factor	  2	  (granulocyte-­‐macrophage)	  B12	   Csf2rb	   Colony	  stimulating	  factor	  2	  receptor,	  beta	  C01	   Csf3	   Colony	  stimulating	  factor	  3	  (granulocyte)	  C02	   Cxcl1	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  1	  C03	   Cxcl10	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10	  C04	   Cxcl3	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  3	  C05	   Cxcl9	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  9	  C06	   Egfr	   Epidermal	  growth	  factor	  receptor	  C07	   Egr2	   Early	  growth	  response	  2	  C08	   F3	   Coagulation	  factor	  III	  C09	   F8	   Coagulation	  factor	  VIII	  C10	   Fas	   Fas	  (TNF	  receptor	  superfamily	  member	  6)	  C11	   Fasl	   Fas	  ligand	  (TNF	  superfamily,	  member	  6)	  C12	   Gadd45b	   Growth	  arrest	  and	  DNA-­‐damage-­‐inducible	  45	  beta	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  D01	   Icam1	   Intercellular	  adhesion	  molecule	  1	  D02	   Ifnb1	   Interferon	  beta	  1,	  fibroblast	  D03	   Ifng	   Interferon	  gamma	  D04	   Il12b	   Interleukin	  12B	  D05	   Il15	   Interleukin	  15	  D06	   Il1a	   Interleukin	  1	  alpha	  D07	   Il1b	   Interleukin	  1	  beta	  D08	   Il1r2	   Interleukin	  1	  receptor,	  type	  II	  D09	   Il1rn	   Interleukin	  1	  receptor	  antagonist	  D10	   Il2	   Interleukin	  2	  D11	   Il2ra	   Interleukin	  2	  receptor,	  alpha	  chain	  D12	   Il4	   Interleukin	  4	  E01	   Il6	   Interleukin	  6	  E02	   Ins2	   Insulin	  II	  E03	   Irf1	   Interferon	  regulatory	  factor	  1	  E04	   Lta	   Lymphotoxin	  A	  E05	   Ltb	   Lymphotoxin	  B	  E06	   Map2k6	   Mitogen-­‐activated	  protein	  kinase	  kinase	  6	  E07	   Mitf	   Microphthalmia-­‐associated	  transcription	  factor	  E08	   Mmp9	   Matrix	  metallopeptidase	  9	  E09	   Myc	   Myelocytomatosis	  oncogene	  E10	   Myd88	   Myeloid	  differentiation	  primary	  response	  gene	  88	  E11	   Ncoa3	   Nuclear	  receptor	  coactivator	  3	  E12	   NF-­‐κB1	   Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  1	  F01	   NF-­‐κB2	   Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  2	  F02	   NF-­‐κBia	   Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  inhibitor	  F03	   Nqo1	   NAD(P)H	  dehydrogenase,	  quinone	  1	  F04	   Nr4a2	   Nuclear	  receptor	  subfamily	  4,	  group	  A,	  member	  2	  F05	   Pdgfb	   Platelet	  derived	  growth	  factor,	  B	  polypeptide	  F06	   Plau	   Plasminogen	  activator,	  urokinase	  F07	   Ptgs2	   Prostaglandin-­‐endoperoxide	  synthase	  2	  F08	   Rel	   Reticuloendotheliosis	  oncogene	  F09	   Rela	   V-­‐rel	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A	  (avian)	  F10	   Relb	   Avian	  reticuloendotheliosis	  viral	  (v-­‐rel)	  oncogene	  related	  B	  F11	   Sele	   Selectin,	  endothelial	  cell	  F12	   Selp	   Selectin,	  platelet	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  G01	   Snap25	   Synaptosomal-­‐associated	  protein	  25	  G02	   Sod2	   Superoxide	  dismutase	  2,	  mitochondrial	  G03	   Stat1	   Signal	  transducer	  and	  activator	  of	  transcription	  1	  G04	   Stat3	   Signal	  transducer	  and	  activator	  of	  transcription	  3	  G05	   Stat5b	   Signal	  transducer	  and	  activator	  of	  transcription	  5B	  G06	   Tnf	   Tumor	  necrosis	  factor	  G07	   Tnfrsf1b	   Tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  1b	  G08	   Tnfsf10	   Tumor	  necrosis	  factor	  (ligand)	  superfamily,	  member	  10	  G09	   Traf2	   Tnf	  receptor-­‐associated	  factor	  2	  G10	   Trp53	   Transformation	  related	  protein	  53	  G11	   Vcam1	   Vascular	  cell	  adhesion	  molecule	  1	  G12	   Xiap	   X-­‐linked	  inhibitor	  of	  apoptosis	  H01	   Actb	   Actin,	  beta	  H02	   B2m	   Beta-­‐2	  microglobulin	  H03	   Gapdh	   Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  H04	   Gusb	   Glucuronidase,	  beta	  H05	   Hsp90ab1	   Heat	  shock	  protein	  90	  alpha	  (cytosolic),	  class	  B	  member	  1	  H06	   MGDC	   Mouse	  Genomic	  DNA	  Contamination	  H07	   RTC	   Reverse	  Transcription	  Control	  H08	   RTC	   Reverse	  Transcription	  Control	  H09	   RTC	   Reverse	  Transcription	  Control	  H10	   PPC	   Positive	  PCR	  Control	  H11	   PPC	   Positive	  PCR	  Control	  H12	   PPC	   Positive	  PCR	  Control	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Supplemental	  table	  1:	  List	  of	  target	  gene	  included	  in	  RT-­‐PCR	  array.	  H01-­‐H05	  lists	  the	  housekeeping	  genes.	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